action_type,activity_comment,activity_id,activity_properties,assay_chembl_id,assay_description,assay_type,assay_variant_accession,assay_variant_mutation,bao_endpoint,bao_format,bao_label,canonical_smiles,data_validity_comment,data_validity_description,document_chembl_id,document_journal,document_year,ligand_efficiency,molecule_chembl_id,molecule_pref_name,parent_molecule_chembl_id,pchembl_value,potential_duplicate,qudt_units,record_id,relation,src_id,standard_flag,standard_relation,standard_text_value,standard_type,standard_units,standard_upper_value,standard_value,target_chembl_id,target_organism,target_pref_name,target_tax_id,text_value,toid,type,units,uo_units,upper_value,value
,,150600,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)NCCc1ccccc1,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '7.62', 'le': '0.14', 'lle': '3.53', 'sei': '3.01'}",CHEMBL32704,,CHEMBL32704,6.28,0,http://www.openphacts.org/units/Nanomolar,50962,=,1,1,=,,IC50,nM,,520.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.52
,,151869,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)NCc1ccccc1,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '8.21', 'le': '0.15', 'lle': '3.95', 'sei': '3.18'}",CHEMBL33248,,CHEMBL33248,6.66,0,http://www.openphacts.org/units/Nanomolar,50957,=,1,1,=,,IC50,nM,,220.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.22
,,154283,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](C)c1ccccc1,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '8.07', 'le': '0.15', 'lle': '3.39', 'sei': '3.18'}",CHEMBL285069,,CHEMBL285069,6.66,0,http://www.openphacts.org/units/Nanomolar,50945,=,1,1,=,,IC50,nM,,220.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.22
,,157966,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)NC1CC1,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '8.38', 'le': '0.16', 'lle': '4.71', 'sei': '3.05'}",CHEMBL286124,,CHEMBL286124,6.38,0,http://www.openphacts.org/units/Nanomolar,50956,=,1,1,=,,IC50,nM,,420.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.42
,,172695,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)c1ccccc1,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '9.70', 'le': '0.18', 'lle': '4.32', 'sei': '3.85'}",CHEMBL285686,,CHEMBL285686,7.58,0,http://www.openphacts.org/units/Nanomolar,50968,=,1,1,=,,IC50,nM,,26.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.026
,,173783,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)N[C@@H](C)C(=O)c1cccc2ccccc12,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '6.78', 'le': '0.13', 'lle': '2.19', 'sei': '2.71'}",CHEMBL284771,,CHEMBL284771,6.12,0,http://www.openphacts.org/units/Nanomolar,50958,=,1,1,=,,IC50,nM,,750.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.75
,,174938,[],CHEMBL752797,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)NC(C)C(=O)O,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '8.68', 'le': '0.16', 'lle': '5.91', 'sei': '2.79'}",CHEMBL423300,,CHEMBL423300,6.89,0,http://www.openphacts.org/units/Nanomolar,50969,=,1,1,=,,IC50,nM,,130.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.13
,,178835,[],CHEMBL857687,Binding inhibition of hepatitis C virus NS3.4A protease 2 using a reverse phase HPLC based assay; <0.2 (0.15),B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC(NC(=O)[C@@H]1C[C@@H](OC(=O)N2CCc3ccccc3C2)CN1C(=O)[C@H](NC(=O)[C@H](NC(=O)c1cnccn1)C(C)C)C(C)C)C(=O)C(=O)NCC(=O)O,,,CHEMBL1147624,Bioorg Med Chem Lett,2004,"{'bei': '9.54', 'le': '0.18', 'lle': '6.84', 'sei': '3.02'}",CHEMBL285260,,CHEMBL285260,7.43,0,http://www.openphacts.org/units/Nanomolar,50944,=,1,1,=,,IC50,nM,,37.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.037
,,234541,[],CHEMBL752809,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '10.12', 'le': '0.20', 'lle': '2.08', 'sei': '4.17'}",CHEMBL116118,,CHEMBL116118,4.00,0,http://www.openphacts.org/units/Nanomolar,214282,=,1,1,=,,IC50,nM,,99000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,99.0
,,234542,[],CHEMBL752806,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 hr preincubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '11.51', 'le': '0.22', 'lle': '2.63', 'sei': '4.74'}",CHEMBL116118,,CHEMBL116118,4.55,0,http://www.openphacts.org/units/Nanomolar,214282,=,1,1,=,,IC50,nM,,28000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,28.0
,,234543,[],CHEMBL752810,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL116118,,CHEMBL116118,,0,http://www.openphacts.org/units/Nanomolar,214282,=,1,1,=,,IC50,nM,,341000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,341.0
,,234544,[],CHEMBL752807,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 h pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL116118,,CHEMBL116118,,0,http://www.openphacts.org/units/Nanomolar,214282,=,1,1,=,,IC50,nM,,172000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,172.0
,,235829,[],CHEMBL752808,Inhibitory concentration against hepatitis C virus NS3/4A protease on 2 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '5.81', 'le': '0.12', 'lle': '5.77', 'sei': '1.57'}",CHEMBL111936,,CHEMBL111936,4.16,0,http://www.openphacts.org/units/Nanomolar,214276,=,1,1,=,,IC50,nM,,69000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,69.0
,,235830,[],CHEMBL752806,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 hr preincubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '6.59', 'le': '0.13', 'lle': '6.33', 'sei': '1.78'}",CHEMBL111936,,CHEMBL111936,4.72,0,http://www.openphacts.org/units/Nanomolar,214276,=,1,1,=,,IC50,nM,,19000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,19.0
,,235831,[],CHEMBL752809,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '5.81', 'le': '0.12', 'lle': '5.77', 'sei': '1.57'}",CHEMBL111936,,CHEMBL111936,4.16,0,http://www.openphacts.org/units/Nanomolar,214276,=,1,1,=,,IC50,nM,,69000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,69.0
,,235832,[],CHEMBL752810,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL111936,,CHEMBL111936,,0,http://www.openphacts.org/units/Nanomolar,214276,>,1,1,>,,IC50,nM,,400000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,400.0
,,235833,[],CHEMBL752807,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 h pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(C)=O)C(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL111936,,CHEMBL111936,,0,http://www.openphacts.org/units/Nanomolar,214276,=,1,1,=,,IC50,nM,,284000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,284.0
,,243846,[],CHEMBL752806,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 hr preincubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '10.07', 'le': '0.20', 'lle': '3.02', 'sei': '3.84'}",CHEMBL326331,,CHEMBL326331,4.35,0,http://www.openphacts.org/units/Nanomolar,214281,=,1,1,=,,IC50,nM,,45000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,45.0
,,243847,[],CHEMBL752809,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '9.40', 'le': '0.19', 'lle': '2.73', 'sei': '3.59'}",CHEMBL326331,,CHEMBL326331,4.06,0,http://www.openphacts.org/units/Nanomolar,214281,=,1,1,=,,IC50,nM,,88000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,88.0
,,243848,[],CHEMBL752810,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL326331,,CHEMBL326331,,0,http://www.openphacts.org/units/Nanomolar,214281,=,1,1,=,,IC50,nM,,193000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,193.0
,,243849,[],CHEMBL752807,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 h pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL326331,,CHEMBL326331,,0,http://www.openphacts.org/units/Nanomolar,214281,=,1,1,=,,IC50,nM,,194000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,194.0
,,247841,[],CHEMBL752806,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 hr preincubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '10.59', 'le': '0.22', 'lle': '3.24', 'sei': '4.04'}",CHEMBL112200,,CHEMBL112200,4.57,0,http://www.openphacts.org/units/Nanomolar,214284,=,1,1,=,,IC50,nM,,27000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,27.0
,,247842,[],CHEMBL752809,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '9.75', 'le': '0.20', 'lle': '2.88', 'sei': '3.72'}",CHEMBL112200,,CHEMBL112200,4.21,0,http://www.openphacts.org/units/Nanomolar,214284,=,1,1,=,,IC50,nM,,62000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,62.0
,,247843,[],CHEMBL752810,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL112200,,CHEMBL112200,,0,http://www.openphacts.org/units/Nanomolar,214284,=,1,1,=,,IC50,nM,,182000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,182.0
,,247844,[],CHEMBL752807,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 h pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL112200,,CHEMBL112200,,0,http://www.openphacts.org/units/Nanomolar,214284,=,1,1,=,,IC50,nM,,140000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,140.0
,,257542,[],CHEMBL752809,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL115136,,CHEMBL115136,,0,http://www.openphacts.org/units/Nanomolar,214280,>,1,1,>,,IC50,nM,,400000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,400.0
,,257543,[],CHEMBL752806,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 hr preincubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL115136,,CHEMBL115136,,0,http://www.openphacts.org/units/Nanomolar,214280,=,1,1,=,,IC50,nM,,147000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,147.0
,,257544,[],CHEMBL752810,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL115136,,CHEMBL115136,,0,http://www.openphacts.org/units/Nanomolar,214280,=,1,1,=,,IC50,nM,,216000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,216.0
,,257545,[],CHEMBL752807,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 h pre-incubation in fluorogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H]1C(=O)N(C(C)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1134977,Bioorg Med Chem Lett,2002,,CHEMBL115136,,CHEMBL115136,,0,http://www.openphacts.org/units/Nanomolar,214280,=,1,1,=,,IC50,nM,,447000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,447.0
,,264137,[],CHEMBL752809,Inhibitory concentration against hepatitis C virus NS3/4A protease on 4 hr pre-incubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '10.48', 'le': '0.21', 'lle': '3.19', 'sei': '4.00'}",CHEMBL419930,,CHEMBL419930,4.52,0,http://www.openphacts.org/units/Nanomolar,214283,=,1,1,=,,IC50,nM,,30000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,30.0
,,264138,[],CHEMBL752806,Inhibitory concentration against hepatitis C virus NS3/4A protease on 18 hr preincubation in chromogenic assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C(=O)N(S(C)(=O)=O)[C@H]2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)[C@H]12,,,CHEMBL1134977,Bioorg Med Chem Lett,2002,"{'bei': '10.79', 'le': '0.22', 'lle': '3.33', 'sei': '4.12'}",CHEMBL419930,,CHEMBL419930,4.66,0,http://www.openphacts.org/units/Nanomolar,214283,=,1,1,=,,IC50,nM,,22000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,22.0
,,514822,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(=O)NCc1ccccc1,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '7.59', 'le': '0.15', 'lle': '6.43', 'sei': '2.16'}",CHEMBL2370184,,CHEMBL2370184,6.19,0,http://www.openphacts.org/units/Nanomolar,168204,=,1,1,=,,IC50,nM,,640.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.64
,,514827,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(N)=O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370173,,CHEMBL2370173,,0,http://www.openphacts.org/units/Nanomolar,168200,>,1,1,>,,IC50,nM,,1000000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,1000.0
,,516059,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL1790295,,CHEMBL1790295,,0,http://www.openphacts.org/units/Nanomolar,168216,=,1,1,=,,IC50,nM,,750000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,750.0
,,516060,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(F)(F)F,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2311162,,CHEMBL2311162,,0,http://www.openphacts.org/units/Nanomolar,168210,=,1,1,=,,IC50,nM,,160000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,160.0
,,518596,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(F)(F)C(F)(F)F,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '5.12', 'le': '0.10', 'lle': '3.46', 'sei': '1.59'}",CHEMBL2370191,,CHEMBL2370191,4.10,0,http://www.openphacts.org/units/Nanomolar,168209,=,1,1,=,,IC50,nM,,79000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,79.0
,,519891,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370188,,CHEMBL2370188,,0,http://www.openphacts.org/units/Nanomolar,168197,=,1,1,=,,IC50,nM,,500000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,500.0
,,525094,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)NCc1ccccc1,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '5.44', 'le': '0.10', 'lle': '4.09', 'sei': '1.59'}",CHEMBL2370189,,CHEMBL2370189,4.28,0,http://www.openphacts.org/units/Nanomolar,168198,=,1,1,=,,IC50,nM,,52000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,52.0
,,527818,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370177,,CHEMBL2370177,,0,http://www.openphacts.org/units/Nanomolar,168214,=,1,1,=,,IC50,nM,,780000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,780.0
,,527819,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(F)(F)C(F)(F)F,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.15', 'le': '0.12', 'lle': '4.28', 'sei': '1.91'}",CHEMBL2370192,,CHEMBL2370192,4.92,0,http://www.openphacts.org/units/Nanomolar,168205,=,1,1,=,,IC50,nM,,12000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,12.0
,,529229,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](C=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '8.73', 'le': '0.17', 'lle': '6.89', 'sei': '2.31'}",CHEMBL2370193,,CHEMBL2370193,5.96,0,http://www.openphacts.org/units/Nanomolar,168207,=,1,1,=,,IC50,nM,,1100.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,1.1
,,531931,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)C(C)C,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.48', 'le': '0.13', 'lle': '6.46', 'sei': '1.64'}",CHEMBL295605,,CHEMBL295605,4.55,0,http://www.openphacts.org/units/Nanomolar,168194,=,1,1,=,,IC50,nM,,28000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,28.0
,,535846,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370178,,CHEMBL2370178,,0,http://www.openphacts.org/units/Nanomolar,168215,=,1,1,=,,IC50,nM,,250000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,250.0
,,535847,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)NC,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370172,,CHEMBL2370172,,0,http://www.openphacts.org/units/Nanomolar,168199,=,1,1,=,,IC50,nM,,160000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,160.0
,,537172,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)OC,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.69', 'le': '0.13', 'lle': '5.72', 'sei': '1.79'}",CHEMBL2370174,,CHEMBL2370174,4.77,0,http://www.openphacts.org/units/Nanomolar,168202,=,1,1,=,,IC50,nM,,17000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,17.0
,,539804,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370187,,CHEMBL2370187,,0,http://www.openphacts.org/units/Nanomolar,168196,=,1,1,=,,IC50,nM,,190000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,190.0
,,539805,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(F)(F)F,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.20', 'le': '0.12', 'lle': None, 'sei': '1.81'}",CHEMBL310738,,CHEMBL310738,4.66,0,http://www.openphacts.org/units/Nanomolar,168206,=,1,1,=,,IC50,nM,,22000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,22.0
,,540974,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370195,,CHEMBL2370195,,0,http://www.openphacts.org/units/Nanomolar,168213,=,1,1,=,,IC50,nM,,800000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,800.0
,,540975,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.83', 'le': '0.13', 'lle': '5.81', 'sei': '1.72'}",CHEMBL306027,,CHEMBL306027,4.77,0,http://www.openphacts.org/units/Nanomolar,168212,=,1,1,=,,IC50,nM,,17000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,17.0
,,540980,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](C=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '7.32', 'le': '0.14', 'lle': '5.93', 'sei': '1.94'}",CHEMBL2370196,,CHEMBL2370196,5.00,0,http://www.openphacts.org/units/Nanomolar,168211,=,1,1,=,,IC50,nM,,10000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,10.0
,,540981,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)C(=O)NCc1ccccc1,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.98', 'le': '0.13', 'lle': '5.94', 'sei': '1.99'}",CHEMBL2370179,,CHEMBL2370179,5.70,0,http://www.openphacts.org/units/Nanomolar,168208,=,1,1,=,,IC50,nM,,2000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,2.0
,,544940,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](CO)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL2370176,,CHEMBL2370176,,0,http://www.openphacts.org/units/Nanomolar,168203,=,1,1,=,,IC50,nM,,280000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,280.0
,,549854,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1130603,Bioorg Med Chem Lett,1998,,CHEMBL72695,,CHEMBL72695,,0,http://www.openphacts.org/units/Nanomolar,168195,=,1,1,=,,IC50,nM,,150000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,150.0
,,551114,[],CHEMBL752791,Inhibition of hepatitis C virus (HCV) NS3 protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)OCc1ccccc1,,,CHEMBL1130603,Bioorg Med Chem Lett,1998,"{'bei': '6.38', 'le': '0.12', 'lle': '4.41', 'sei': '1.89'}",CHEMBL2370171,,CHEMBL2370171,5.03,0,http://www.openphacts.org/units/Nanomolar,168201,=,1,1,=,,IC50,nM,,9300.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,9.3
,,714959,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COC(=O)c1ccc(CCNC(=O)C(CS)NC(=O)[C@H](CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)OCC(C)C)cc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '7.63', 'le': '0.15', 'lle': '3.08', 'sei': '2.52'}",CHEMBL116193,,CHEMBL116193,4.77,0,http://www.openphacts.org/units/Nanomolar,220876,=,1,1,=,,IC50,nM,,17000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,17.0
,,716115,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@@H](NC(=O)[C@H](NC(=O)OC(C)(C)C)C(C)C)C(=O)N[C@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '13.22', 'le': '0.26', 'lle': '4.48', 'sei': '4.20'}",CHEMBL116690,,CHEMBL116690,6.34,0,http://www.openphacts.org/units/Nanomolar,220871,=,1,1,=,,IC50,nM,,460.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,460.0
,,717454,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)NCCCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '6.48', 'le': None, 'lle': None, 'sei': None}",CHEMBL214100,,CHEMBL214100,6.68,0,http://www.openphacts.org/units/Nanomolar,220873,=,1,1,=,,IC50,nM,,210.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.21
,,718683,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(F)F)C(=O)O)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '7.95', 'le': '0.15', 'lle': '5.74', 'sei': '2.28'}",CHEMBL421233,,CHEMBL421233,7.40,0,http://www.openphacts.org/units/Nanomolar,220866,=,1,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,,718684,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)NCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.30', 'le': None, 'lle': None, 'sei': None}",CHEMBL406457,,CHEMBL406457,8.70,0,http://www.openphacts.org/units/Nanomolar,220868,=,1,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,,719754,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(F)F)C(=O)NOCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '7.14', 'le': None, 'lle': None, 'sei': None}",CHEMBL216266,,CHEMBL216266,7.40,0,http://www.openphacts.org/units/Nanomolar,220867,=,1,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,,719755,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)C(CCC(=O)O)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CS)C(=O)NCc1ccccc1,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1145951,J Med Chem,2003,,CHEMBL325232,,CHEMBL325232,,0,http://www.openphacts.org/units/Nanomolar,220882,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,720832,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)NCCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.03', 'le': None, 'lle': None, 'sei': None}",CHEMBL265015,,CHEMBL265015,8.15,0,http://www.openphacts.org/units/Nanomolar,220870,=,1,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.007
,,724248,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)COC(=O)NC(CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CS)C(=O)NCCc1ccccc1C(=O)O,,,CHEMBL1145951,J Med Chem,2003,,CHEMBL326056,,CHEMBL326056,,0,http://www.openphacts.org/units/Nanomolar,220874,>,1,1,>,,IC50,nM,,100000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,100.0
,,725363,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)NCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '6.59', 'le': None, 'lle': None, 'sei': None}",CHEMBL263598,,CHEMBL263598,6.60,0,http://www.openphacts.org/units/Nanomolar,220869,=,1,1,=,,IC50,nM,,250.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.25
,,725364,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)NCCc1ccccc1Cl)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.28', 'le': None, 'lle': None, 'sei': None}",CHEMBL263172,,CHEMBL263172,8.70,0,http://www.openphacts.org/units/Nanomolar,220892,=,1,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.002
,,726653,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCc1ccccc1)C(=O)N[C@@H](CS)C(=O)NCCc1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '7.34', 'le': '0.14', 'lle': '2.13', 'sei': '2.86'}",CHEMBL117986,,CHEMBL117986,4.40,0,http://www.openphacts.org/units/Nanomolar,220890,=,1,1,=,,IC50,nM,,40000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,40.0
,,730253,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C(=O)N[C@@H](CS)C(=O)NCCc1ccccc1,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1145951,J Med Chem,2003,,CHEMBL420317,,CHEMBL420317,,0,http://www.openphacts.org/units/Nanomolar,220891,>,1,1,>,,IC50,nM,,400000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,400.0
,,732500,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)NC1Cc2ccccc2C1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '5.61', 'le': None, 'lle': None, 'sei': None}",CHEMBL265298,,CHEMBL265298,5.77,0,http://www.openphacts.org/units/Nanomolar,220895,=,1,1,=,,IC50,nM,,1700.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,1.7
,,732501,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CS)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1145951,J Med Chem,2003,,CHEMBL2370491,,CHEMBL2370491,,0,http://www.openphacts.org/units/Nanomolar,220880,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,736319,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COC(=O)c1ccccc1CCNC(=O)C(CS)NC(=O)[C@H](CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)OCC(C)C,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '6.83', 'le': '0.14', 'lle': '2.58', 'sei': '2.26'}",CHEMBL325667,,CHEMBL325667,4.27,0,http://www.openphacts.org/units/Nanomolar,220878,=,1,1,=,,IC50,nM,,54000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,54.0
,,736320,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COC(=O)c1cccc(CCNC(=O)C(CS)NC(=O)[C@H](CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)OCC(C)C)c1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '7.37', 'le': '0.15', 'lle': '2.91', 'sei': '2.43'}",CHEMBL324117,,CHEMBL324117,4.60,0,http://www.openphacts.org/units/Nanomolar,220877,=,1,1,=,,IC50,nM,,25000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,25.0
,,738965,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)C(CCC(=O)O)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CS)C(=O)NCCc1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.06', 'le': '0.16', 'lle': '2.52', 'sei': '2.80'}",CHEMBL115574,,CHEMBL115574,4.57,0,http://www.openphacts.org/units/Nanomolar,220889,=,1,1,=,,IC50,nM,,27000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,27.0
,,740162,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)COC(=O)NC(CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CS)C(=O)NCCc1cccc(C(=O)O)c1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.25', 'le': '0.16', 'lle': '3.44', 'sei': '2.52'}",CHEMBL116398,,CHEMBL116398,5.04,0,http://www.openphacts.org/units/Nanomolar,220888,=,1,1,=,,IC50,nM,,9200.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,9.2
,,742927,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CC(F)F)C(=O)NCCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.12', 'le': None, 'lle': None, 'sei': None}",CHEMBL409677,,CHEMBL409677,8.40,0,http://www.openphacts.org/units/Nanomolar,220872,=,1,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,,744345,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)Nc1ccccc1C1CC1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '5.66', 'le': None, 'lle': None, 'sei': None}",CHEMBL263695,,CHEMBL263695,5.82,0,http://www.openphacts.org/units/Nanomolar,220894,=,1,1,=,,IC50,nM,,1500.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,1.5
,,745571,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)NCCC1CCCCC1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '5.69', 'le': None, 'lle': None, 'sei': None}",CHEMBL264008,,CHEMBL264008,5.81,0,http://www.openphacts.org/units/Nanomolar,220896,=,1,1,=,,IC50,nM,,1540.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,1.54
,,745572,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)COC(=O)NC(CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CS)C(=O)NCCc1ccc(C(=O)O)cc1Cl,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '9.54', 'le': '0.20', 'lle': '3.89', 'sei': '3.07'}",CHEMBL326490,,CHEMBL326490,6.16,0,http://www.openphacts.org/units/Nanomolar,220886,=,1,1,=,,IC50,nM,,700.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.7
,,746775,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)COC(=O)NC(CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CS)C(=O)NCCc1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.33', 'le': '0.17', 'lle': '2.81', 'sei': '2.90'}",CHEMBL116143,,CHEMBL116143,4.72,0,http://www.openphacts.org/units/Nanomolar,220879,=,1,1,=,,IC50,nM,,19000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,19.0
,,748166,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](CS)C(=O)N(C)CCc1ccccc1)C(c1ccccc1)c1ccccc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '4.03', 'le': None, 'lle': None, 'sei': None}",CHEMBL267752,,CHEMBL267752,4.16,0,http://www.openphacts.org/units/Nanomolar,220893,=,1,1,=,,IC50,nM,,70000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,70.0
,,748167,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)C(CCC(=O)O)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CS)C(=O)NCCc1ccccc1Cl,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.63', 'le': '0.18', 'lle': '2.49', 'sei': '3.18'}",CHEMBL116399,,CHEMBL116399,5.19,0,http://www.openphacts.org/units/Nanomolar,220881,=,1,1,=,,IC50,nM,,6500.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,6.5
,,749355,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)COC(=O)NC(CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CS)C(=O)NCCc1ccc(C(=O)O)cc1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '9.33', 'le': '0.19', 'lle': '4.10', 'sei': '2.85'}",CHEMBL332056,,CHEMBL332056,5.70,0,http://www.openphacts.org/units/Nanomolar,220887,=,1,1,=,,IC50,nM,,2000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,2.0
,,751791,[],CHEMBL772933,Inhibitory activity against Hepatitis C NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COC(=O)c1ccc(CCNC(=O)C(CS)NC(=O)[C@H](CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)OCC(C)C)c(Cl)c1,,,CHEMBL1145951,J Med Chem,2003,"{'bei': '8.34', 'le': '0.17', 'lle': '3.14', 'sei': '2.90'}",CHEMBL116239,,CHEMBL116239,5.50,0,http://www.openphacts.org/units/Nanomolar,220875,=,1,1,=,,IC50,nM,,3200.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,3.2
,,753748,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C1CCCC1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '12.70', 'le': '0.25', 'lle': '4.03', 'sei': '4.25'}",CHEMBL320324,,CHEMBL320324,6.42,0,http://www.openphacts.org/units/Nanomolar,212444,=,1,1,=,,IC50,nM,,380.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.38
,,756956,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](O)c1ccc(Cl)cc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '10.89', 'le': '0.22', 'lle': '3.19', 'sei': '3.68'}",CHEMBL113467,,CHEMBL113467,4.89,0,http://www.openphacts.org/units/Nanomolar,212457,=,1,1,=,,IC50,nM,,13000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,13.0
,,758199,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](O)C1CCCCC1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '12.26', 'le': '0.24', 'lle': '3.90', 'sei': '3.88'}",CHEMBL420303,,CHEMBL420303,5.16,0,http://www.openphacts.org/units/Nanomolar,212454,=,1,1,=,,IC50,nM,,7000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,7.0
,,759171,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](O)c1ccc(C(F)(F)F)cc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '9.44', 'le': '0.19', 'lle': '2.49', 'sei': '3.43'}",CHEMBL323980,,CHEMBL323980,4.55,0,http://www.openphacts.org/units/Nanomolar,212458,=,1,1,=,,IC50,nM,,28000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,28.0
,,762380,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](O)c1ccccc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '13.33', 'le': '0.26', 'lle': '4.48', 'sei': '4.16'}",CHEMBL69077,,CHEMBL69077,5.52,0,http://www.openphacts.org/units/Nanomolar,212453,=,1,1,=,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,3.0
,,763531,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)Cn1nc(-c2ccccc2)c2ccccc2c1=O)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL112053,,CHEMBL112053,,0,http://www.openphacts.org/units/Nanomolar,212449,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,764544,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)CC(c1ccccc1)c1ccccc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL113402,,CHEMBL113402,,0,http://www.openphacts.org/units/Nanomolar,212447,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,772304,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc([C@@H](O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O)cc1,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '10.99', 'le': '0.22', 'lle': '3.84', 'sei': '3.44'}",CHEMBL332245,,CHEMBL332245,4.89,0,http://www.openphacts.org/units/Nanomolar,212456,=,1,1,=,,IC50,nM,,13000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,13.0
,,773605,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O)c(OC)c1OC,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL115275,,CHEMBL115275,,0,http://www.openphacts.org/units/Nanomolar,212445,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,774719,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc(C(Oc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O)cc1,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '9.12', 'le': '0.18', 'lle': '1.60', 'sei': '3.62'}",CHEMBL115495,,CHEMBL115495,4.75,0,http://www.openphacts.org/units/Nanomolar,212451,=,1,1,=,,IC50,nM,,18000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,18.0
,,775892,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](O)c1ccccc1Cl)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '9.77', 'le': '0.20', 'lle': '2.69', 'sei': '3.30'}",CHEMBL112557,,CHEMBL112557,4.39,0,http://www.openphacts.org/units/Nanomolar,212459,=,1,1,=,,IC50,nM,,41000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,41.0
,,776841,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@@H](O)c1ccccc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL115621,,CHEMBL115621,,0,http://www.openphacts.org/units/Nanomolar,212452,>,1,1,>,,IC50,nM,,100000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,100.0
,,781456,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)c1cccc(Oc2ccccc2)c1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL420133,,CHEMBL420133,,0,http://www.openphacts.org/units/Nanomolar,212450,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,781457,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)C(Cc1ccccc1)c1ccccc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL115359,,CHEMBL115359,,0,http://www.openphacts.org/units/Nanomolar,212448,>,1,1,>,,IC50,nM,,30000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,30.0
,,782480,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)[C@H](O)c1cccs1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '11.29', 'le': '0.23', 'lle': '3.63', 'sei': '3.57'}",CHEMBL114125,,CHEMBL114125,4.75,0,http://www.openphacts.org/units/Nanomolar,212455,=,1,1,=,,IC50,nM,,18000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,18.0
,,783623,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)Cn1c(-c2ccccc2)nc2ccccc21)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL1136041,Bioorg Med Chem Lett,2002,,CHEMBL112067,,CHEMBL112067,,0,http://www.openphacts.org/units/Nanomolar,212446,>,1,1,>,,IC50,nM,,200000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,200.0
,,787075,[],CHEMBL752805,Inhibitory concentration evaluated against NS3/4A protease.,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC(=O)C(Sc1ccccc1)c1ccccc1)C(=O)N[C@@H](CC(F)F)C(=O)C(=O)O,,,CHEMBL1136041,Bioorg Med Chem Lett,2002,"{'bei': '10.18', 'le': '0.20', 'lle': '1.31', 'sei': '4.58'}",CHEMBL112992,,CHEMBL112992,5.16,0,http://www.openphacts.org/units/Nanomolar,212460,=,1,1,=,,IC50,nM,,7000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,7.0
,,1108191,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1cccc(CNC(=O)C(=O)[C@@H](CC(F)(F)F)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(C)(C)C)c1,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '7.94', 'le': None, 'lle': None, 'sei': None}",CHEMBL405033,,CHEMBL405033,8.22,0,http://www.openphacts.org/units/Nanomolar,226023,=,1,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,,1118978,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](NC(=O)C(=O)[C@@H](CC(F)(F)F)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(C)(C)C)c1ccc2ccccc2c1,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '7.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL412493,,CHEMBL412493,8.10,0,http://www.openphacts.org/units/Nanomolar,226022,=,1,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,,1122434,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](N)C(=O)C(N)=O)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '9.61', 'le': '0.19', 'lle': '10.44', 'sei': '2.19'}",CHEMBL120084,,CHEMBL120084,8.15,0,http://www.openphacts.org/units/Nanomolar,226020,=,1,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,,1126210,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(F)(F)F)C(=O)C(=O)N[C@@H](C)c1ccc2ccccc2c1)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '7.85', 'le': None, 'lle': None, 'sei': None}",CHEMBL427986,,CHEMBL427986,8.40,0,http://www.openphacts.org/units/Nanomolar,226019,=,1,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,,1128627,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(F)(F)F)C(=O)C(=O)NCc1ccccc1)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '8.35', 'le': None, 'lle': None, 'sei': None}",CHEMBL262654,,CHEMBL262654,8.40,0,http://www.openphacts.org/units/Nanomolar,226018,=,1,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,,1128628,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(F)(F)F)C(=O)C(=O)N[C@H](c1ccccc1)C(C)C)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '7.78', 'le': None, 'lle': None, 'sei': None}",CHEMBL269187,,CHEMBL269187,8.15,0,http://www.openphacts.org/units/Nanomolar,226026,=,1,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,,1130985,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CCCC[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(C)(C)C)C(=O)C(N)=O,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '8.94', 'le': '0.17', 'lle': '7.97', 'sei': '2.30'}",CHEMBL331243,,CHEMBL331243,7.96,0,http://www.openphacts.org/units/Nanomolar,226021,=,1,1,=,,IC50,nM,,11.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.0
,,1132051,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@H](NC(=O)C(=O)[C@@H](CC(F)(F)F)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(C)(C)C)c1ccccc1,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '7.89', 'le': None, 'lle': None, 'sei': None}",CHEMBL405304,,CHEMBL405304,8.15,0,http://www.openphacts.org/units/Nanomolar,226025,=,1,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,,1134732,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(F)(F)F)C(=O)C(=O)N[C@H](C)c1ccccc1)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '5.84', 'le': None, 'lle': None, 'sei': None}",CHEMBL414922,,CHEMBL414922,5.96,0,http://www.openphacts.org/units/Nanomolar,226028,=,1,1,=,,IC50,nM,,1100.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1100.0
,,1138484,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(F)(F)F)C(=O)C(=O)N[C@@H](C)c1ccccc1)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '8.23', 'le': None, 'lle': None, 'sei': None}",CHEMBL263772,,CHEMBL263772,8.40,0,http://www.openphacts.org/units/Nanomolar,226024,=,1,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,,1141133,[],CHEMBL750632,Inhibition of hepatitis c virus Non structural protein 3 protease/Non structural protein 4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccccc1C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(F)(F)F)C(=O)C(=O)NCc1ccc(O)cc1)C(C)(C)C,,,CHEMBL1134166,Bioorg Med Chem Lett,2001,"{'bei': '8.22', 'le': None, 'lle': None, 'sei': None}",CHEMBL261963,,CHEMBL261963,8.40,0,http://www.openphacts.org/units/Nanomolar,226027,=,1,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,,15066230,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(C)C)n3)nc2c1,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '11.74', 'le': '0.23', 'lle': '3.05', 'sei': '5.02'}",CHEMBL297884,CILUPREVIR,CHEMBL297884,9.10,0,http://www.openphacts.org/units/Nanomolar,2249203,=,1,1,=,,IC50,nM,,0.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.8
,,15066231,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N[C@@]5(C(=O)NS(=O)(=O)C6CC6)C[C@@H]5/C=C\CCCCN(C)C(=O)N34)cc(-c3ccccc3)nc2c1,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '8.17', 'le': '0.16', 'lle': '1.61', 'sei': '3.82'}",CHEMBL3326536,,CHEMBL3326536,5.62,0,http://www.openphacts.org/units/Nanomolar,2249204,=,1,1,=,,IC50,nM,,2400.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2400.0
,,15066232,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@H]3C[C@@H]4C(=O)N[C@@]5(C(=O)NS(=O)(=O)C6CC6)C[C@@H]5/C=C\CCCCN(C)C(=O)N34)cc(-c3ccccc3)nc2c1,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '9.53', 'le': '0.18', 'lle': '2.55', 'sei': '4.45'}",CHEMBL3326537,,CHEMBL3326537,6.56,0,http://www.openphacts.org/units/Nanomolar,2249205,=,1,1,=,,IC50,nM,,278.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,278.0
,,15066233,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5CC5)NC(=O)N34)cc(-c3ccccc3)nc2c1,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '10.68', 'le': '0.20', 'lle': '3.34', 'sei': '4.99'}",CHEMBL3326538,,CHEMBL3326538,7.35,0,http://www.openphacts.org/units/Nanomolar,2249206,=,1,1,=,,IC50,nM,,45.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,45.0
,,15066234,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@H]3C[C@@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5CC5)NC(=O)N34)cc(-c3ccccc3)nc2c1,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '12.29', 'le': '0.24', 'lle': '4.45', 'sei': '5.74'}",CHEMBL3326539,,CHEMBL3326539,8.46,0,http://www.openphacts.org/units/Nanomolar,2249207,=,1,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,,15066235,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)N34)cc(-c3nc(C(C)C)cs3)nc2c1F,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '10.11', 'le': '0.20', 'lle': '2.65', 'sei': '4.86'}",CHEMBL3326540,,CHEMBL3326540,7.78,0,http://www.openphacts.org/units/Nanomolar,2249208,=,1,1,=,,IC50,nM,,16.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,16.8
,,15066236,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)N34)cc(-c3nc(C(C)C)cs3)nc2c1,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '11.83', 'le': '0.23', 'lle': '3.91', 'sei': '5.55'}",CHEMBL3326826,,CHEMBL3326826,8.89,0,http://www.openphacts.org/units/Nanomolar,2249209,=,1,1,=,,IC50,nM,,1.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.3
,,15066237,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5CC5)NC(=O)N34)cc(-c3nc(C(C)C)cs3)nc2c1C,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,,CHEMBL3326827,,CHEMBL3326827,,0,http://www.openphacts.org/units/Nanomolar,2249210,<,1,1,<,,IC50,nM,,1000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1000.0
,,15066238,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5CC5)NC(=O)N34)cc(-c3nc(C(C)C)cs3)nc2c1Cl,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,,CHEMBL3326828,,CHEMBL3326828,,0,http://www.openphacts.org/units/Nanomolar,2249211,<,1,1,<,,IC50,nM,,1000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1000.0
,,15066239,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)N34)cc(-c3nc(C(C)C)cs3)nc2c1C,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '10.69', 'le': '0.21', 'lle': '2.89', 'sei': '5.11'}",CHEMBL3326829,,CHEMBL3326829,8.18,0,http://www.openphacts.org/units/Nanomolar,2249212,=,1,1,=,,IC50,nM,,6.6,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.6
,,15066240,[],CHEMBL3362860,Inhibition of full length Hepatitis C virus genotype 1b Con1 NS3/4A by FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(OC[C@@H]3C[C@H]4C(=O)N(C)CCCC/C=C\[C@H]5C[C@]5(C(=O)NS(=O)(=O)C5(C)CC5)NC(=O)N34)cc(-c3nc(C(C)C)cs3)nc2c1Cl,,,CHEMBL3351305,Bioorg Med Chem Lett,2014,"{'bei': '11.05', 'le': '0.22', 'lle': '3.05', 'sei': '5.42'}",CHEMBL3326830,,CHEMBL3326830,8.68,0,http://www.openphacts.org/units/Nanomolar,2249213,=,1,1,=,,IC50,nM,,2.1,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.1
,,16527664,[],CHEMBL3791341,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant using Ac-C(Eu)DDMEEAbu[COO]ASK(QSY7)-amide as substrate preincubated for 30 mins followed by substrate addition measured after 2.5 hrs by TRF assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,Cc1nc2ccccc2c2c1O[C@]1(CC2)C[C@H]2C(=O)N[C@]3(C(=O)NS(=O)(=O)C4(C)CC4)C[C@H]3/C=C\CCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)N2C1,,,CHEMBL3785042,ACS Med Chem Lett,2016,"{'bei': '13.44', 'le': '0.26', 'lle': '5.59', 'sei': '5.82'}",CHEMBL3787685,,CHEMBL3787685,10.08,0,http://www.openphacts.org/units/Nanomolar,2766592,=,1,1,=,,IC50,nM,,0.083,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.083
,,16527665,[],CHEMBL3791341,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant using Ac-C(Eu)DDMEEAbu[COO]ASK(QSY7)-amide as substrate preincubated for 30 mins followed by substrate addition measured after 2.5 hrs by TRF assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,COc1ccc2nc(C(F)(F)F)c3c(c2c1)CC[C@]1(C[C@H]2C(=O)N[C@]4(C(=O)NS(=O)(=O)C5(C)CC5)C[C@H]4/C=C\CCCCC[C@H](NC(=O)OCC(C)C)C(=O)N2C1)O3,,,CHEMBL3785042,ACS Med Chem Lett,2016,"{'bei': '13.19', 'le': '0.26', 'lle': '5.93', 'sei': '6.03'}",CHEMBL3785323,,CHEMBL3785323,11.00,0,http://www.openphacts.org/units/Nanomolar,2768380,=,1,1,=,,IC50,nM,,0.01,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.01
,,16527666,[],CHEMBL3791341,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant using Ac-C(Eu)DDMEEAbu[COO]ASK(QSY7)-amide as substrate preincubated for 30 mins followed by substrate addition measured after 2.5 hrs by TRF assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3785042,ACS Med Chem Lett,2016,"{'bei': '13.92', 'le': '0.27', 'lle': '7.38', 'sei': '5.47'}",CHEMBL2063090,GRAZOPREVIR ANHYDROUS,CHEMBL2063090,10.68,0,http://www.openphacts.org/units/Nanomolar,2768381,=,1,1,=,,IC50,nM,,0.021,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.021
,,16527697,[],CHEMBL3791341,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant using Ac-C(Eu)DDMEEAbu[COO]ASK(QSY7)-amide as substrate preincubated for 30 mins followed by substrate addition measured after 2.5 hrs by TRF assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ccc3ccccc3n2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1(C)CC1,,,CHEMBL3785042,ACS Med Chem Lett,2016,"{'bei': '12.23', 'le': '0.24', 'lle': '4.96', 'sei': '4.93'}",CHEMBL3787419,,CHEMBL3787419,8.54,0,http://www.openphacts.org/units/Nanomolar,2766590,=,1,1,=,,IC50,nM,,2.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.9
,,16527698,[],CHEMBL3791341,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant using Ac-C(Eu)DDMEEAbu[COO]ASK(QSY7)-amide as substrate preincubated for 30 mins followed by substrate addition measured after 2.5 hrs by TRF assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]2(CCc3c(c(C)nc4ccccc34)O2)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1(C)CC1,,,CHEMBL3785042,ACS Med Chem Lett,2016,"{'bei': '14.01', 'le': '0.27', 'lle': '6.13', 'sei': '5.97'}",CHEMBL3786672,,CHEMBL3786672,10.34,0,http://www.openphacts.org/units/Nanomolar,2766591,=,1,1,=,,IC50,nM,,0.046,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.046
,,16800347,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '13.33', 'le': '0.26', 'lle': '6.92', 'sei': '5.24'}",CHEMBL2063090,GRAZOPREVIR ANHYDROUS,CHEMBL2063090,10.22,0,http://www.openphacts.org/units/Nanomolar,2808761,=,1,1,=,,IC50,nM,,0.06,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.06
,,16800348,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,COc1ccc2nc(C(F)(F)F)c3c(c2c1)CC[C@]1(C[C@H]2C(=O)N[C@]4(C(=O)NS(=O)(=O)C5(C)CC5)C[C@H]4/C=C\CCCCC[C@H](NC(=O)OCC(C)C)C(=O)N2C1)O3,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '13.19', 'le': '0.26', 'lle': '5.93', 'sei': '6.03'}",CHEMBL3785323,,CHEMBL3785323,11.00,1,http://www.openphacts.org/units/Nanomolar,2808762,=,1,1,=,,IC50,nM,,0.01,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.01
,,16800349,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4C[C@H]4OC(=O)N[C@@H](C(C)(C)C)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '13.51', 'le': '0.26', 'lle': '6.48', 'sei': '5.87'}",CHEMBL3928647,,CHEMBL3928647,10.70,0,http://www.openphacts.org/units/Nanomolar,2808763,=,1,1,=,,IC50,nM,,0.02,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.02
,,16800350,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4C[C@H]4OC(=O)N[C@@H](C(C)(C)C)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1(C)CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.78', 'le': '0.25', 'lle': '5.69', 'sei': '5.65'}",CHEMBL3956226,,CHEMBL3956226,10.30,0,http://www.openphacts.org/units/Nanomolar,2808764,=,1,1,=,,IC50,nM,,0.05,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.05
,,16800351,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4C[C@H]4OC(=O)N[C@@H](C(C)(C)C)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.72', 'le': '0.25', 'lle': '5.65', 'sei': '5.54'}",CHEMBL3962860,,CHEMBL3962860,10.10,0,http://www.openphacts.org/units/Nanomolar,2808765,=,1,1,=,,IC50,nM,,0.08,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.08
,,16800352,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4C[C@H]4OC(=O)N[C@@H](C4(C)CCCCC4)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.38', 'le': '0.24', 'lle': '5.15', 'sei': '5.65'}",CHEMBL3893915,,CHEMBL3893915,10.30,0,http://www.openphacts.org/units/Nanomolar,2808766,=,1,1,=,,IC50,nM,,0.05,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.05
,,16800353,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4C[C@H]4OC(=O)N[C@@H](C4(C)CCCCC4)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1(C)CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.00', 'le': '0.23', 'lle': '4.61', 'sei': '5.57'}",CHEMBL3952146,,CHEMBL3952146,10.15,0,http://www.openphacts.org/units/Nanomolar,2808767,=,1,1,=,,IC50,nM,,0.07,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.07
,,16800354,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4CCC[C@H]4OC(=O)N[C@@H](C(C)(C)C)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.83', 'le': '0.25', 'lle': '5.52', 'sei': '5.77'}",CHEMBL3924454,,CHEMBL3924454,10.52,0,http://www.openphacts.org/units/Nanomolar,2808768,=,1,1,=,,IC50,nM,,0.03,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.03
,,16800355,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@]23CCc4c(c(nc5ccc(OC)cc45)CCCCC[C@@H]4CCC[C@H]4OC(=O)N[C@@H](C(C)(C)C)C(=O)N1C2)O3)C(=O)NS(=O)(=O)C1(C)CC1,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.47', 'le': '0.24', 'lle': '5.01', 'sei': '5.70'}",CHEMBL3943429,,CHEMBL3943429,10.40,0,http://www.openphacts.org/units/Nanomolar,2808769,=,1,1,=,,IC50,nM,,0.04,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.04
,,16800356,[],CHEMBL3868490,Inhibition of HCV genotype 1b NS3/4A protease R155K mutant assessed as substrate cleavage using Ac-C(Eu)DDMEEAbu(COO)ASK(QSY7)-amide as substrate incubated for 30 mins prior to substrate addition measured after 2.5 hrs by time-resolved fluorescence assay,B,A3EZI9,R155K,BAO_0000190,BAO_0000019,assay format,COc1ccc2nc3c4c(c2c1)CC[C@]1(C[C@H]2C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C\CCCCC[C@H](NC(=O)O[C@@H]5CCC[C@H]5CCCCC3)C(=O)N2C1)O4,,,CHEMBL3867486,ACS Med Chem Lett,2016,"{'bei': '12.18', 'le': '0.23', 'lle': '4.62', 'sei': '5.65'}",CHEMBL3915464,,CHEMBL3915464,10.30,0,http://www.openphacts.org/units/Nanomolar,2808770,=,1,1,=,,IC50,nM,,0.05,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.05
,231119,17619123,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.64', 'le': '0.19', 'lle': '3.16', 'sei': '4.15'}",CHEMBL3645575,,CHEMBL3645575,6.40,0,http://www.openphacts.org/units/Nanomolar,2518781,=,37,1,=,,IC50,nM,,400.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,400.0
,231120,17619124,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '7.88', 'le': '0.15', 'lle': '2.35', 'sei': '3.34'}",CHEMBL3645576,,CHEMBL3645576,6.12,0,http://www.openphacts.org/units/Nanomolar,2518782,=,37,1,=,,IC50,nM,,750.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,750.0
,231121,17619125,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.90', 'le': '0.19', 'lle': '4.59', 'sei': '4.64'}",CHEMBL3645577,,CHEMBL3645577,8.22,0,http://www.openphacts.org/units/Nanomolar,2518783,=,37,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,231122,17619126,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN(CC)C1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.14', 'le': '0.18', 'lle': '4.36', 'sei': '4.20'}",CHEMBL3645578,,CHEMBL3645578,7.46,0,http://www.openphacts.org/units/Nanomolar,2518784,=,37,1,=,,IC50,nM,,35.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.0
,231123,17619127,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCOCC1,,,CHEMBL3639192,,2013,"{'bei': '6.53', 'le': '0.13', 'lle': '2.17', 'sei': '2.69'}",CHEMBL3645579,,CHEMBL3645579,5.18,0,http://www.openphacts.org/units/Nanomolar,2518785,=,37,1,=,,IC50,nM,,6650.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6650.0
,231124,17619128,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCOCC1,,,CHEMBL3639192,,2013,"{'bei': '8.68', 'le': '0.17', 'lle': '4.49', 'sei': '3.94'}",CHEMBL3645580,,CHEMBL3645580,7.35,0,http://www.openphacts.org/units/Nanomolar,2518786,=,37,1,=,,IC50,nM,,45.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,45.0
,231125,17619129,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN(CC)C1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCOCC1,,,CHEMBL3639192,,2013,"{'bei': '7.63', 'le': '0.15', 'lle': '4.02', 'sei': '3.40'}",CHEMBL3645581,,CHEMBL3645581,6.35,0,http://www.openphacts.org/units/Nanomolar,2518787,=,37,1,=,,IC50,nM,,450.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,450.0
,231126,17619130,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CCF)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCOCC1,,,CHEMBL3639192,,2013,"{'bei': '7.67', 'le': '0.15', 'lle': '4.10', 'sei': '3.50'}",CHEMBL3645582,,CHEMBL3645582,6.52,0,http://www.openphacts.org/units/Nanomolar,2518788,=,37,1,=,,IC50,nM,,300.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,300.0
,231127,17619131,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](N1CCCC1=O)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.40', 'le': '0.18', 'lle': '4.13', 'sei': '4.23'}",CHEMBL3645583,,CHEMBL3645583,7.00,0,http://www.openphacts.org/units/Nanomolar,2518789,=,37,1,=,,IC50,nM,,100.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,100.0
,231128,17619132,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(C)(C)N1CCCC1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.81', 'le': '0.17', 'lle': '3.95', 'sei': '4.05'}",CHEMBL3645584,,CHEMBL3645584,7.19,0,http://www.openphacts.org/units/Nanomolar,2518790,=,37,1,=,,IC50,nM,,65.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,65.0
,231129,17619133,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.43', 'le': '0.18', 'lle': '4.46', 'sei': '4.34'}",CHEMBL3645585,,CHEMBL3645585,7.70,0,http://www.openphacts.org/units/Nanomolar,2518791,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231130,17619134,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.22', 'le': '0.18', 'lle': '4.55', 'sei': '4.17'}",CHEMBL3645586,,CHEMBL3645586,7.40,0,http://www.openphacts.org/units/Nanomolar,2518792,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231131,17619135,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.95', 'le': '0.19', 'lle': '4.36', 'sei': '4.81'}",CHEMBL3645587,,CHEMBL3645587,8.52,0,http://www.openphacts.org/units/Nanomolar,2518793,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231132,17619136,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(C)(C)N1CCCC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.12', 'le': '0.20', 'lle': '4.75', 'sei': '4.81'}",CHEMBL3645588,,CHEMBL3645588,8.52,0,http://www.openphacts.org/units/Nanomolar,2518794,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231133,17619137,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.33', 'le': '0.20', 'lle': '4.93', 'sei': '4.91'}",CHEMBL3645589,,CHEMBL3645589,8.70,0,http://www.openphacts.org/units/Nanomolar,2518795,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231134,17619138,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.26', 'le': '0.20', 'lle': '4.87', 'sei': '4.87'}",CHEMBL3645590,,CHEMBL3645590,8.64,0,http://www.openphacts.org/units/Nanomolar,2518796,=,37,1,=,,IC50,nM,,2.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.3
,231135,17619139,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.39', 'le': '0.20', 'lle': '5.22', 'sei': '4.85'}",CHEMBL3645591,,CHEMBL3645591,8.60,0,http://www.openphacts.org/units/Nanomolar,2518797,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231136,17619140,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.66', 'le': '0.19', 'lle': '4.62', 'sei': '4.51'}",CHEMBL3645592,,CHEMBL3645592,8.00,0,http://www.openphacts.org/units/Nanomolar,2518798,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231137,17619141,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CN(C(C)C)C1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.77', 'le': '0.17', 'lle': '4.02', 'sei': '4.09'}",CHEMBL3645593,,CHEMBL3645593,7.26,0,http://www.openphacts.org/units/Nanomolar,2518799,=,37,1,=,,IC50,nM,,55.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,55.0
,231138,17619142,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CCF)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.58', 'le': '0.17', 'lle': '3.96', 'sei': '4.03'}",CHEMBL3645594,,CHEMBL3645594,7.16,0,http://www.openphacts.org/units/Nanomolar,2518800,=,37,1,=,,IC50,nM,,70.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,70.0
,231139,17619143,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.14', 'le': '0.18', 'lle': '4.22', 'sei': '4.20'}",CHEMBL3645595,,CHEMBL3645595,7.46,0,http://www.openphacts.org/units/Nanomolar,2518801,=,37,1,=,,IC50,nM,,35.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.0
,231140,17619144,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.75', 'le': '0.17', 'lle': '4.17', 'sei': '3.96'}",CHEMBL3645596,,CHEMBL3645596,7.02,0,http://www.openphacts.org/units/Nanomolar,2518802,=,37,1,=,,IC50,nM,,95.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,95.0
,231141,17619145,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CN(C(C)C)C1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '7.98', 'le': '0.16', 'lle': '3.70', 'sei': '3.61'}",CHEMBL3645597,,CHEMBL3645597,6.40,0,http://www.openphacts.org/units/Nanomolar,2518803,=,37,1,=,,IC50,nM,,400.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,400.0
,231142,17619146,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(C)(C)N1CCCCC1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.66', 'le': '0.17', 'lle': '3.56', 'sei': '4.05'}",CHEMBL3645598,,CHEMBL3645598,7.19,0,http://www.openphacts.org/units/Nanomolar,2518804,=,37,1,=,,IC50,nM,,65.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,65.0
,231143,17619147,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C(C)(C)N1CCCCC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.46', 'le': '0.18', 'lle': '3.94', 'sei': '4.57'}",CHEMBL3645599,,CHEMBL3645599,8.10,0,http://www.openphacts.org/units/Nanomolar,2518805,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231144,17619148,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CCF)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.10', 'le': '0.18', 'lle': '4.10', 'sei': '4.41'}",CHEMBL3645600,,CHEMBL3645600,7.82,0,http://www.openphacts.org/units/Nanomolar,2518806,=,37,1,=,,IC50,nM,,15.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.0
,231145,17619149,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CCCN1C1CCCC1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.50', 'le': '0.19', 'lle': '4.23', 'sei': '4.51'}",CHEMBL3645601,,CHEMBL3645601,8.00,0,http://www.openphacts.org/units/Nanomolar,2518807,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231146,17619150,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C1CCCC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.02', 'le': '0.19', 'lle': '4.40', 'sei': '4.91'}",CHEMBL3645602,,CHEMBL3645602,8.70,0,http://www.openphacts.org/units/Nanomolar,2518808,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231147,17619151,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1Cc3[nH]cnc3CN1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.96', 'le': '0.17', 'lle': '5.60', 'sei': '3.44'}",CHEMBL3645603,,CHEMBL3645603,7.40,0,http://www.openphacts.org/units/Nanomolar,2518809,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231148,17619152,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.66', 'le': '0.17', 'lle': '3.36', 'sei': '4.06'}",CHEMBL3645604,,CHEMBL3645604,7.21,0,http://www.openphacts.org/units/Nanomolar,2518810,=,37,1,=,,IC50,nM,,62.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,62.0
,231149,17619153,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C1CCCC1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.46', 'le': '0.18', 'lle': '3.94', 'sei': '4.57'}",CHEMBL3645605,,CHEMBL3645605,8.10,0,http://www.openphacts.org/units/Nanomolar,2518811,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231150,17619154,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C1CCCC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.20', 'le': '0.20', 'lle': '4.31', 'sei': '5.08'}",CHEMBL3645606,,CHEMBL3645606,9.00,0,http://www.openphacts.org/units/Nanomolar,2518812,=,37,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,231151,17619155,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CCOC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.70', 'le': '0.19', 'lle': '5.06', 'sei': '4.53'}",CHEMBL3645607,,CHEMBL3645607,8.46,0,http://www.openphacts.org/units/Nanomolar,2518813,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231152,17619156,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.73', 'le': '0.19', 'lle': '3.97', 'sei': '4.71'}",CHEMBL3645608,,CHEMBL3645608,8.35,0,http://www.openphacts.org/units/Nanomolar,2518814,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231153,17619157,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1CCCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.66', 'le': '0.19', 'lle': '3.83', 'sei': '4.81'}",CHEMBL3645609,,CHEMBL3645609,8.52,0,http://www.openphacts.org/units/Nanomolar,2518815,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231154,17619158,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.04', 'le': '0.20', 'lle': '4.69', 'sei': '4.77'}",CHEMBL3645610,,CHEMBL3645610,8.46,0,http://www.openphacts.org/units/Nanomolar,2518816,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231155,17619159,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.07', 'le': '0.20', 'lle': '4.71', 'sei': '4.78'}",CHEMBL3645611,,CHEMBL3645611,8.48,0,http://www.openphacts.org/units/Nanomolar,2518817,=,37,1,=,,IC50,nM,,3.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.3
,231156,17619160,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.21', 'le': '0.20', 'lle': '5.08', 'sei': '4.77'}",CHEMBL3645612,,CHEMBL3645612,8.46,0,http://www.openphacts.org/units/Nanomolar,2518818,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231157,17619161,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.39', 'le': '0.20', 'lle': '5.22', 'sei': '4.85'}",CHEMBL3645613,,CHEMBL3645613,8.60,0,http://www.openphacts.org/units/Nanomolar,2518819,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231158,17619162,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CCN1C(C)(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.76', 'le': '0.19', 'lle': '4.45', 'sei': '4.64'}",CHEMBL3645614,,CHEMBL3645614,8.22,0,http://www.openphacts.org/units/Nanomolar,2518820,=,37,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,231159,17619163,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.23', 'le': '0.20', 'lle': '5.51', 'sei': '4.85'}",CHEMBL3645615,,CHEMBL3645615,9.05,0,http://www.openphacts.org/units/Nanomolar,2518821,=,37,1,=,,IC50,nM,,0.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.9
,231160,17619164,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.84', 'le': '0.17', 'lle': '5.02', 'sei': '3.54'}",CHEMBL3645616,,CHEMBL3645616,7.40,0,http://www.openphacts.org/units/Nanomolar,2518822,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231161,17619165,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCOCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.90', 'le': '0.17', 'lle': '5.37', 'sei': '3.45'}",CHEMBL3645617,,CHEMBL3645617,7.22,0,http://www.openphacts.org/units/Nanomolar,2518823,=,37,1,=,,IC50,nM,,60.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,60.0
,231162,17619166,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCOCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.12', 'le': '0.18', 'lle': '4.81', 'sei': '4.19'}",CHEMBL3645618,,CHEMBL3645618,7.82,0,http://www.openphacts.org/units/Nanomolar,2518824,=,37,1,=,,IC50,nM,,15.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.0
,231163,17619167,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CC[C@@H](F)C1,,,CHEMBL3639192,,2013,"{'bei': '10.30', 'le': '0.20', 'lle': '4.89', 'sei': '5.08'}",CHEMBL3645619,,CHEMBL3645619,9.00,0,http://www.openphacts.org/units/Nanomolar,2518825,=,37,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,231164,17619168,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CC[C@H](F)C1,,,CHEMBL3639192,,2013,"{'bei': '9.95', 'le': '0.19', 'lle': '4.59', 'sei': '4.91'}",CHEMBL3645620,,CHEMBL3645620,8.70,0,http://www.openphacts.org/units/Nanomolar,2518826,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231165,17619169,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.72', 'le': '0.19', 'lle': '4.16', 'sei': '4.69'}",CHEMBL3645621,,CHEMBL3645621,8.32,0,http://www.openphacts.org/units/Nanomolar,2518827,=,37,1,=,,IC50,nM,,4.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.8
,231166,17619170,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.92', 'le': '0.21', 'lle': '5.67', 'sei': '5.10'}",CHEMBL3645622,,CHEMBL3645622,9.05,0,http://www.openphacts.org/units/Nanomolar,2518828,=,37,1,=,,IC50,nM,,0.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.9
,231167,17619171,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C1CCC1,,,CHEMBL3639192,,2013,"{'bei': '9.75', 'le': '0.19', 'lle': '3.93', 'sei': '4.78'}",CHEMBL3645623,,CHEMBL3645623,8.48,0,http://www.openphacts.org/units/Nanomolar,2518829,=,37,1,=,,IC50,nM,,3.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.3
,231168,17619172,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC1CC1,,,CHEMBL3639192,,2013,"{'bei': '9.68', 'le': '0.19', 'lle': '4.01', 'sei': '4.75'}",CHEMBL3645624,,CHEMBL3645624,8.42,0,http://www.openphacts.org/units/Nanomolar,2518830,=,37,1,=,,IC50,nM,,3.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.8
,231169,17619173,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(Nc1cccnc1)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '7.88', 'le': '0.15', 'lle': '2.19', 'sei': '3.50'}",CHEMBL3645625,,CHEMBL3645625,5.94,0,http://www.openphacts.org/units/Nanomolar,2518831,=,37,1,=,,IC50,nM,,1150.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1150.0
,231170,17619174,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)c1ccccc1,,,CHEMBL3639192,,2013,"{'bei': '9.64', 'le': '0.19', 'lle': '3.40', 'sei': '4.85'}",CHEMBL3645626,,CHEMBL3645626,8.60,0,http://www.openphacts.org/units/Nanomolar,2518832,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231171,17619175,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C1CC1,,,CHEMBL3639192,,2013,"{'bei': '10.24', 'le': '0.20', 'lle': '4.61', 'sei': '4.95'}",CHEMBL3645627,,CHEMBL3645627,8.77,0,http://www.openphacts.org/units/Nanomolar,2518833,=,37,1,=,,IC50,nM,,1.7,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.7
,231172,17619176,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CCOC)C1CC1,,,CHEMBL3639192,,2013,"{'bei': '9.56', 'le': '0.19', 'lle': '4.42', 'sei': '4.61'}",CHEMBL3645628,,CHEMBL3645628,8.60,0,http://www.openphacts.org/units/Nanomolar,2518834,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231173,17619177,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)OC,,,CHEMBL3639192,,2013,"{'bei': '10.46', 'le': '0.20', 'lle': '5.29', 'sei': '4.75'}",CHEMBL3645629,,CHEMBL3645629,8.85,0,http://www.openphacts.org/units/Nanomolar,2518835,=,37,1,=,,IC50,nM,,1.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.4
,231174,17619178,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CCOC,,,CHEMBL3639192,,2013,"{'bei': '9.26', 'le': '0.18', 'lle': '4.46', 'sei': '4.34'}",CHEMBL3645630,,CHEMBL3645630,8.10,0,http://www.openphacts.org/units/Nanomolar,2518836,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231175,17619179,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)NC1CCC1,,,CHEMBL3639192,,2013,"{'bei': '9.56', 'le': '0.19', 'lle': '3.98', 'sei': '4.40'}",CHEMBL3645631,,CHEMBL3645631,8.19,0,http://www.openphacts.org/units/Nanomolar,2518837,=,37,1,=,,IC50,nM,,6.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.5
,231176,17619180,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.04', 'le': '0.20', 'lle': '4.69', 'sei': '4.77'}",CHEMBL3645632,,CHEMBL3645632,8.46,0,http://www.openphacts.org/units/Nanomolar,2518838,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231177,17619181,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C1CCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.21', 'le': '0.20', 'lle': '5.08', 'sei': '4.77'}",CHEMBL3645633,,CHEMBL3645633,8.46,0,http://www.openphacts.org/units/Nanomolar,2518839,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231178,17619182,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)CC1(CC(N)=O)CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '7.92', 'le': '0.16', 'lle': '2.85', 'sei': '3.14'}",CHEMBL3645634,,CHEMBL3645634,5.90,0,http://www.openphacts.org/units/Nanomolar,2518840,=,37,1,=,,IC50,nM,,1250.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1250.0
,231179,17619183,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)CC1(CC#N)CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.43', 'le': '0.16', 'lle': '2.03', 'sei': '3.63'}",CHEMBL3645635,,CHEMBL3645635,6.12,0,http://www.openphacts.org/units/Nanomolar,2518841,=,37,1,=,,IC50,nM,,750.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,750.0
,231180,17619184,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.66', 'le': '0.21', 'lle': '4.98', 'sei': '5.08'}",CHEMBL3645636,,CHEMBL3645636,9.00,0,http://www.openphacts.org/units/Nanomolar,2518842,=,37,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,231181,17619185,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.75', 'le': '0.21', 'lle': '5.29', 'sei': '5.03'}",CHEMBL3645637,,CHEMBL3645637,8.92,0,http://www.openphacts.org/units/Nanomolar,2518843,=,37,1,=,,IC50,nM,,1.2,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.2
,231182,17619186,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C1CCCC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.84', 'le': '0.19', 'lle': '3.76', 'sei': '4.91'}",CHEMBL3645638,,CHEMBL3645638,8.70,0,http://www.openphacts.org/units/Nanomolar,2518844,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231183,17619187,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.73', 'le': '0.19', 'lle': '3.94', 'sei': '4.71'}",CHEMBL3645639,,CHEMBL3645639,8.35,0,http://www.openphacts.org/units/Nanomolar,2518845,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231184,17619188,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)C(NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1CCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.51', 'le': '0.18', 'lle': '3.96', 'sei': '4.66'}",CHEMBL3645640,,CHEMBL3645640,8.26,0,http://www.openphacts.org/units/Nanomolar,2518846,=,37,1,=,,IC50,nM,,5.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.5
,231185,17619189,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)C1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)(C)C)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.97', 'le': '0.18', 'lle': '4.69', 'sei': '4.13'}",CHEMBL3645641,,CHEMBL3645641,7.70,0,http://www.openphacts.org/units/Nanomolar,2518847,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231186,17619190,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)C1C[C@@]2(CN1C(=O)[C@@H](NC(=O)c1cccc(C(=O)NCCC)c1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.00', 'le': '0.16', 'lle': '2.73', 'sei': '3.46'}",CHEMBL3645642,,CHEMBL3645642,6.02,0,http://www.openphacts.org/units/Nanomolar,2518848,=,37,1,=,,IC50,nM,,950.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,950.0
,231187,17619191,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cccc(N(C)C)n1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.58', 'le': '0.17', 'lle': '3.63', 'sei': '3.84'}",CHEMBL3645643,,CHEMBL3645643,7.30,0,http://www.openphacts.org/units/Nanomolar,2518849,=,37,1,=,,IC50,nM,,50.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,50.0
,231188,17619192,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cccnc1N(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.76', 'le': '0.17', 'lle': '3.79', 'sei': '3.92'}",CHEMBL3645644,,CHEMBL3645644,7.46,0,http://www.openphacts.org/units/Nanomolar,2518850,=,37,1,=,,IC50,nM,,35.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.0
,231189,17619193,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1CC(F)(F)F)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.13', 'le': '0.16', 'lle': '4.10', 'sei': '3.97'}",CHEMBL3645645,,CHEMBL3645645,7.40,0,http://www.openphacts.org/units/Nanomolar,2518851,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231190,17619194,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1CC(F)F)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.02', 'le': '0.16', 'lle': '4.14', 'sei': '3.84'}",CHEMBL3645646,,CHEMBL3645646,7.16,0,http://www.openphacts.org/units/Nanomolar,2518852,=,37,1,=,,IC50,nM,,70.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,70.0
,231191,17619195,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1CCF)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.95', 'le': '0.18', 'lle': '5.11', 'sei': '4.19'}",CHEMBL3645647,,CHEMBL3645647,7.82,0,http://www.openphacts.org/units/Nanomolar,2518853,=,37,1,=,,IC50,nM,,15.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.0
,231192,17619196,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1CC(F)F)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '7.93', 'le': '0.16', 'lle': '3.79', 'sei': '3.85'}",CHEMBL3645648,,CHEMBL3645648,7.19,0,http://www.openphacts.org/units/Nanomolar,2518854,=,37,1,=,,IC50,nM,,65.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,65.0
,231193,17619197,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1CCF)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.47', 'le': '0.17', 'lle': '4.42', 'sei': '4.03'}",CHEMBL3645649,,CHEMBL3645649,7.52,0,http://www.openphacts.org/units/Nanomolar,2518855,=,37,1,=,,IC50,nM,,30.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,30.0
,231194,17619198,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1C(=O)OCCF)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '7.73', 'le': '0.15', 'lle': '4.25', 'sei': '3.33'}",CHEMBL3639445,,CHEMBL3639445,7.10,0,http://www.openphacts.org/units/Nanomolar,2518856,=,37,1,=,,IC50,nM,,80.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,80.0
,231195,17619199,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.72', 'le': '0.21', 'lle': '5.03', 'sei': '5.10'}",CHEMBL3645650,,CHEMBL3645650,9.05,0,http://www.openphacts.org/units/Nanomolar,2518857,=,37,1,=,,IC50,nM,,0.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.9
,231196,17619200,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)C1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C1CCCNC1=O)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.98', 'le': '0.18', 'lle': '4.83', 'sei': '3.55'}",CHEMBL3645651,,CHEMBL3645651,6.19,0,http://www.openphacts.org/units/Nanomolar,2518858,=,37,1,=,,IC50,nM,,650.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,650.0
,231197,17619201,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.19', 'le': '0.20', 'lle': '4.58', 'sei': '4.85'}",CHEMBL3645652,,CHEMBL3645652,8.60,0,http://www.openphacts.org/units/Nanomolar,2518859,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231198,17619202,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)C(NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1CCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.00', 'le': '0.19', 'lle': '4.15', 'sei': '4.91'}",CHEMBL3645653,,CHEMBL3645653,8.70,0,http://www.openphacts.org/units/Nanomolar,2518860,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231199,17619203,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)C1CCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.12', 'le': '0.20', 'lle': '4.77', 'sei': '4.74'}",CHEMBL3645654,,CHEMBL3645654,8.40,0,http://www.openphacts.org/units/Nanomolar,2518861,=,37,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,231200,17619204,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.39', 'le': '0.20', 'lle': '5.22', 'sei': '4.85'}",CHEMBL3645655,,CHEMBL3645655,8.60,0,http://www.openphacts.org/units/Nanomolar,2518862,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231201,17619205,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC(F)F,,,CHEMBL3639192,,2013,"{'bei': '9.88', 'le': '0.19', 'lle': '4.44', 'sei': '4.91'}",CHEMBL3645656,,CHEMBL3645656,8.70,0,http://www.openphacts.org/units/Nanomolar,2518863,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231202,17619206,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.28', 'le': '0.18', 'lle': '4.43', 'sei': '4.41'}",CHEMBL3645657,,CHEMBL3645657,8.22,0,http://www.openphacts.org/units/Nanomolar,2518864,=,37,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,231203,17619207,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.57', 'le': '0.19', 'lle': '4.95', 'sei': '4.47'}",CHEMBL3645658,,CHEMBL3645658,8.35,0,http://www.openphacts.org/units/Nanomolar,2518865,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231204,17619208,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.86', 'le': '0.19', 'lle': '4.11', 'sei': '4.71'}",CHEMBL3645659,,CHEMBL3645659,8.35,0,http://www.openphacts.org/units/Nanomolar,2518866,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231205,17619209,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.66', 'le': '0.19', 'lle': '4.15', 'sei': '4.60'}",CHEMBL3645660,,CHEMBL3645660,8.15,0,http://www.openphacts.org/units/Nanomolar,2518867,=,37,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,231206,17619210,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)C1C[C@@]2(CN1C(=O)[C@@H](NC(=O)c1cccc(C(=O)NC)c1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.69', 'le': '0.17', 'lle': '3.79', 'sei': '3.62'}",CHEMBL3645661,,CHEMBL3645661,6.30,0,http://www.openphacts.org/units/Nanomolar,2518868,=,37,1,=,,IC50,nM,,500.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,500.0
,231207,17619211,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CC(F)(F)CN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.57', 'le': '0.17', 'lle': '3.50', 'sei': '4.24'}",CHEMBL3645662,,CHEMBL3645662,7.52,0,http://www.openphacts.org/units/Nanomolar,2518869,=,37,1,=,,IC50,nM,,30.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,30.0
,231208,17619212,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C1CC1,,,CHEMBL3639192,,2013,"{'bei': '9.54', 'le': '0.19', 'lle': '3.81', 'sei': '4.62'}",CHEMBL3645663,,CHEMBL3645663,8.19,0,http://www.openphacts.org/units/Nanomolar,2518870,=,37,1,=,,IC50,nM,,6.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.5
,231209,17619213,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '10.00', 'le': '0.20', 'lle': '4.67', 'sei': '4.68'}",CHEMBL3645664,,CHEMBL3645664,8.30,0,http://www.openphacts.org/units/Nanomolar,2518871,=,37,1,=,,IC50,nM,,5.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.0
,231210,17619214,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '10.10', 'le': '0.20', 'lle': '4.50', 'sei': '4.81'}",CHEMBL3645665,,CHEMBL3645665,8.52,0,http://www.openphacts.org/units/Nanomolar,2518872,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231211,17619215,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '10.66', 'le': '0.21', 'lle': '5.46', 'sei': '4.91'}",CHEMBL3645666,,CHEMBL3645666,8.70,0,http://www.openphacts.org/units/Nanomolar,2518873,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231212,17619216,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '10.63', 'le': '0.21', 'lle': '5.19', 'sei': '4.98'}",CHEMBL3645667,,CHEMBL3645667,8.82,0,http://www.openphacts.org/units/Nanomolar,2518874,=,37,1,=,,IC50,nM,,1.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.5
,231213,17619217,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.86', 'le': '0.19', 'lle': '4.53', 'sei': '4.68'}",CHEMBL3645668,,CHEMBL3645668,8.30,0,http://www.openphacts.org/units/Nanomolar,2518875,=,37,1,=,,IC50,nM,,5.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.0
,231214,17619218,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C1CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.50', 'le': '0.19', 'lle': '5.14', 'sei': '4.37'}",CHEMBL3645669,,CHEMBL3645669,8.15,0,http://www.openphacts.org/units/Nanomolar,2518876,=,37,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,231215,17619219,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1CC)C1CCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.80', 'le': '0.19', 'lle': '4.76', 'sei': '4.51'}",CHEMBL3645670,,CHEMBL3645670,8.00,0,http://www.openphacts.org/units/Nanomolar,2518877,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231216,17619220,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CCC,,,CHEMBL3639192,,2013,"{'bei': '9.82', 'le': '0.19', 'lle': '4.52', 'sei': '4.60'}",CHEMBL3645671,,CHEMBL3645671,8.15,0,http://www.openphacts.org/units/Nanomolar,2518878,=,37,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,231217,17619221,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.27', 'le': '0.18', 'lle': '4.09', 'sei': '4.34'}",CHEMBL3645672,,CHEMBL3645672,7.70,0,http://www.openphacts.org/units/Nanomolar,2518879,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231218,17619222,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.61', 'le': '0.19', 'lle': '4.15', 'sei': '4.51'}",CHEMBL3645673,,CHEMBL3645673,8.00,0,http://www.openphacts.org/units/Nanomolar,2518880,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231219,17619223,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '10.54', 'le': '0.21', 'lle': '5.36', 'sei': '4.85'}",CHEMBL3645674,,CHEMBL3645674,8.60,0,http://www.openphacts.org/units/Nanomolar,2518881,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231220,17619224,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)c1ccccc1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.85', 'le': '0.19', 'lle': '4.93', 'sei': '4.57'}",CHEMBL3645675,,CHEMBL3645675,8.10,0,http://www.openphacts.org/units/Nanomolar,2518882,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231221,17619225,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)c1ccccc1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.21', 'le': '0.18', 'lle': '4.14', 'sei': '4.34'}",CHEMBL3645676,,CHEMBL3645676,7.70,0,http://www.openphacts.org/units/Nanomolar,2518883,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231222,17619226,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)c1ccccc1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.20', 'le': '0.18', 'lle': '3.87', 'sei': '4.41'}",CHEMBL3645677,,CHEMBL3645677,7.82,0,http://www.openphacts.org/units/Nanomolar,2518884,=,37,1,=,,IC50,nM,,15.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.0
,231223,17619227,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCC(F)(F)CN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.23', 'le': '0.16', 'lle': '2.94', 'sei': '4.14'}",CHEMBL3645678,,CHEMBL3645678,7.35,0,http://www.openphacts.org/units/Nanomolar,2518885,=,37,1,=,,IC50,nM,,45.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,45.0
,231224,17619228,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CCC,,,CHEMBL3639192,,2013,"{'bei': '9.17', 'le': '0.18', 'lle': '3.20', 'sei': '4.51'}",CHEMBL3645679,,CHEMBL3645679,8.00,0,http://www.openphacts.org/units/Nanomolar,2518886,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231225,17619229,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CCC,,,CHEMBL3639192,,2013,"{'bei': '9.53', 'le': '0.19', 'lle': '4.03', 'sei': '4.54'}",CHEMBL3645680,,CHEMBL3645680,8.05,0,http://www.openphacts.org/units/Nanomolar,2518887,=,37,1,=,,IC50,nM,,9.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.0
,231226,17619230,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.58', 'le': '0.19', 'lle': '3.82', 'sei': '4.64'}",CHEMBL3645681,,CHEMBL3645681,8.22,0,http://www.openphacts.org/units/Nanomolar,2518888,=,37,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,231227,17619231,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '10.36', 'le': '0.20', 'lle': '4.97', 'sei': '4.85'}",CHEMBL3645682,,CHEMBL3645682,8.60,0,http://www.openphacts.org/units/Nanomolar,2518889,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231228,17619232,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.28', 'le': '0.18', 'lle': '3.31', 'sei': '4.57'}",CHEMBL3645683,,CHEMBL3645683,8.10,0,http://www.openphacts.org/units/Nanomolar,2518890,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231229,17619233,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.59', 'le': '0.19', 'lle': '4.08', 'sei': '4.57'}",CHEMBL3645684,,CHEMBL3645684,8.10,0,http://www.openphacts.org/units/Nanomolar,2518891,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231230,17619234,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CCC,,,CHEMBL3639192,,2013,"{'bei': '10.32', 'le': '0.20', 'lle': '4.44', 'sei': '4.99'}",CHEMBL3645685,,CHEMBL3645685,8.85,0,http://www.openphacts.org/units/Nanomolar,2518892,=,37,1,=,,IC50,nM,,1.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.4
,231231,17619235,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.72', 'le': '0.19', 'lle': '3.91', 'sei': '4.77'}",CHEMBL3645686,,CHEMBL3645686,8.46,0,http://www.openphacts.org/units/Nanomolar,2518893,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231232,17619236,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CCC,,,CHEMBL3639192,,2013,"{'bei': '9.73', 'le': '0.19', 'lle': '3.94', 'sei': '4.71'}",CHEMBL3645687,,CHEMBL3645687,8.35,0,http://www.openphacts.org/units/Nanomolar,2518894,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231233,17619237,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.59', 'le': '0.19', 'lle': '3.80', 'sei': '4.71'}",CHEMBL3645688,,CHEMBL3645688,8.35,0,http://www.openphacts.org/units/Nanomolar,2518895,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231234,17619238,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.89', 'le': '0.19', 'lle': '4.36', 'sei': '4.71'}",CHEMBL3645689,,CHEMBL3645689,8.35,0,http://www.openphacts.org/units/Nanomolar,2518896,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231235,17619239,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.76', 'le': '0.19', 'lle': '4.02', 'sei': '4.66'}",CHEMBL3645690,,CHEMBL3645690,8.26,0,http://www.openphacts.org/units/Nanomolar,2518897,=,37,1,=,,IC50,nM,,5.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.5
,231236,17619240,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.05', 'le': '0.20', 'lle': '4.72', 'sei': '4.71'}",CHEMBL3645691,,CHEMBL3645691,8.35,0,http://www.openphacts.org/units/Nanomolar,2518898,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231237,17619241,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.54', 'le': '0.19', 'lle': '3.79', 'sei': '4.62'}",CHEMBL3645692,,CHEMBL3645692,8.19,0,http://www.openphacts.org/units/Nanomolar,2518899,=,37,1,=,,IC50,nM,,6.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.5
,231238,17619242,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.17', 'le': '0.18', 'lle': '3.21', 'sei': '4.51'}",CHEMBL3645693,,CHEMBL3645693,8.00,0,http://www.openphacts.org/units/Nanomolar,2518900,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231239,17619243,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.48', 'le': '0.19', 'lle': '3.52', 'sei': '4.60'}",CHEMBL3645694,,CHEMBL3645694,8.15,0,http://www.openphacts.org/units/Nanomolar,2518901,=,37,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,231240,17619244,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.82', 'le': '0.21', 'lle': '5.37', 'sei': '4.99'}",CHEMBL3645695,,CHEMBL3645695,8.85,0,http://www.openphacts.org/units/Nanomolar,2518902,=,37,1,=,,IC50,nM,,1.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.4
,231241,17619245,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.43', 'le': '0.18', 'lle': '3.72', 'sei': '4.57'}",CHEMBL3645696,,CHEMBL3645696,8.10,0,http://www.openphacts.org/units/Nanomolar,2518903,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231242,17619246,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.82', 'le': '0.19', 'lle': '4.89', 'sei': '4.73'}",CHEMBL3645697,,CHEMBL3645697,8.82,0,http://www.openphacts.org/units/Nanomolar,2518904,=,37,1,=,,IC50,nM,,1.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.5
,231243,17619247,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,,CHEMBL3645698,,CHEMBL3645698,,0,http://www.openphacts.org/units/Nanomolar,2518905,<,37,1,<,,IC50,nM,,0.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.3
,231244,17619248,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C(C)(C)C)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.74', 'le': '0.19', 'lle': '5.60', 'sei': '4.41'}",CHEMBL3645699,,CHEMBL3645699,8.22,0,http://www.openphacts.org/units/Nanomolar,2518906,=,37,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,231245,17619249,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCOCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.33', 'le': '0.18', 'lle': '5.62', 'sei': '4.29'}",CHEMBL3645700,,CHEMBL3645700,8.40,0,http://www.openphacts.org/units/Nanomolar,2518907,=,37,1,=,,IC50,nM,,4.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.0
,231246,17619250,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)(C)C)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.15', 'le': '0.20', 'lle': '5.45', 'sei': '4.75'}",CHEMBL3645701,,CHEMBL3645701,8.85,0,http://www.openphacts.org/units/Nanomolar,2518908,=,37,1,=,,IC50,nM,,1.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.4
,231247,17619251,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCOCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.43', 'le': '0.18', 'lle': '6.22', 'sei': '4.20'}",CHEMBL3645702,,CHEMBL3645702,8.22,0,http://www.openphacts.org/units/Nanomolar,2518909,=,37,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,231248,17619252,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)C)C(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.07', 'le': '0.20', 'lle': '5.01', 'sei': '4.57'}",CHEMBL3645703,,CHEMBL3645703,8.10,0,http://www.openphacts.org/units/Nanomolar,2518910,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231249,17619253,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C(C)(C)C)C(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.10', 'le': '0.20', 'lle': '4.78', 'sei': '4.66'}",CHEMBL3645704,,CHEMBL3645704,8.26,0,http://www.openphacts.org/units/Nanomolar,2518911,=,37,1,=,,IC50,nM,,5.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.5
,231250,17619254,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.13', 'le': '0.20', 'lle': '4.53', 'sei': '4.82'}",CHEMBL3645705,,CHEMBL3645705,8.55,0,http://www.openphacts.org/units/Nanomolar,2518912,=,37,1,=,,IC50,nM,,2.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.8
,231251,17619255,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1(C)CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.77', 'le': '0.19', 'lle': '3.72', 'sei': '4.81'}",CHEMBL3645706,,CHEMBL3645706,8.52,0,http://www.openphacts.org/units/Nanomolar,2518913,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231252,17619256,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1(C)CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.83', 'le': '0.19', 'lle': '4.28', 'sei': '4.68'}",CHEMBL3645707,,CHEMBL3645707,8.30,0,http://www.openphacts.org/units/Nanomolar,2518914,=,37,1,=,,IC50,nM,,5.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.0
,231253,17619257,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1(C)CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.59', 'le': '0.19', 'lle': '3.80', 'sei': '4.71'}",CHEMBL3645708,,CHEMBL3645708,8.35,0,http://www.openphacts.org/units/Nanomolar,2518915,=,37,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,231254,17619258,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1(C)CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.68', 'le': '0.19', 'lle': '4.38', 'sei': '4.60'}",CHEMBL3645709,,CHEMBL3645709,8.15,0,http://www.openphacts.org/units/Nanomolar,2518916,=,37,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,231255,17619259,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CCC,,,CHEMBL3639192,,2013,"{'bei': '9.69', 'le': '0.19', 'lle': '3.66', 'sei': '4.77'}",CHEMBL3645710,,CHEMBL3645710,8.46,0,http://www.openphacts.org/units/Nanomolar,2518917,=,37,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,231256,17619260,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.41', 'le': '0.18', 'lle': '3.47', 'sei': '4.57'}",CHEMBL3645711,,CHEMBL3645711,8.10,0,http://www.openphacts.org/units/Nanomolar,2518918,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231257,17619261,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CCCN(C)S(=O)(=O)NC(=O)[C@@]1(NC(=O)[C@@H]2C[C@@]3(CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2CCCCN2C(C)C)C2CCCCC2)C(C)(C)C)C(C)(C)C32CCC2)C[C@H]1CC,,,CHEMBL3639192,,2013,"{'bei': '9.30', 'le': '0.18', 'lle': '3.37', 'sei': '4.51'}",CHEMBL3645712,,CHEMBL3645712,8.00,0,http://www.openphacts.org/units/Nanomolar,2518919,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231258,17619262,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCC(F)(F)C1,,,CHEMBL3639192,,2013,"{'bei': '9.55', 'le': '0.19', 'lle': '4.11', 'sei': '4.81'}",CHEMBL3645713,,CHEMBL3645713,8.52,0,http://www.openphacts.org/units/Nanomolar,2518920,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231259,17619263,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1SCCN1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.51', 'le': '0.19', 'lle': '4.76', 'sei': '4.54'}",CHEMBL3645714,,CHEMBL3645714,8.05,0,http://www.openphacts.org/units/Nanomolar,2518921,=,37,1,=,,IC50,nM,,9.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.0
,231260,17619264,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1(C)CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.64', 'le': '0.19', 'lle': '4.98', 'sei': '4.57'}",CHEMBL3645715,,CHEMBL3645715,8.52,0,http://www.openphacts.org/units/Nanomolar,2518922,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231261,17619265,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1(C)CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.67', 'le': '0.19', 'lle': '4.50', 'sei': '4.73'}",CHEMBL3645716,,CHEMBL3645716,8.82,0,http://www.openphacts.org/units/Nanomolar,2518923,=,37,1,=,,IC50,nM,,1.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.5
,231262,17619266,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.57', 'le': '0.19', 'lle': '4.44', 'sei': '4.62'}",CHEMBL3645717,,CHEMBL3645717,8.62,0,http://www.openphacts.org/units/Nanomolar,2518924,=,37,1,=,,IC50,nM,,2.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.4
,231263,17619267,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1CC)C1CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.82', 'le': '0.19', 'lle': '4.91', 'sei': '4.66'}",CHEMBL3645718,,CHEMBL3645718,8.70,0,http://www.openphacts.org/units/Nanomolar,2518925,=,37,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,231264,17619268,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1(C)CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.80', 'le': '0.19', 'lle': '4.39', 'sei': '4.80'}",CHEMBL3645719,,CHEMBL3645719,8.96,0,http://www.openphacts.org/units/Nanomolar,2518926,=,37,1,=,,IC50,nM,,1.1,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.1
,231265,17619269,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1(C)CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.87', 'le': '0.19', 'lle': '4.95', 'sei': '4.69'}",CHEMBL3645720,,CHEMBL3645720,8.74,0,http://www.openphacts.org/units/Nanomolar,2518927,=,37,1,=,,IC50,nM,,1.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.8
,231266,17619270,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1CCCCC1)C1(C)CCOCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.81', 'le': '0.19', 'lle': '5.15', 'sei': '4.58'}",CHEMBL3645721,,CHEMBL3645721,8.55,0,http://www.openphacts.org/units/Nanomolar,2518928,=,37,1,=,,IC50,nM,,2.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.8
,231267,17619271,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC(F)F,,,CHEMBL3639192,,2013,"{'bei': '9.35', 'le': '0.18', 'lle': '3.71', 'sei': '4.71'}",CHEMBL3645722,,CHEMBL3645722,8.36,0,http://www.openphacts.org/units/Nanomolar,2518929,=,37,1,=,,IC50,nM,,4.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.4
,231268,17619272,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CCF,,,CHEMBL3639192,,2013,"{'bei': '10.14', 'le': '0.20', 'lle': '4.53', 'sei': '5.01'}",CHEMBL3645723,,CHEMBL3645723,8.89,0,http://www.openphacts.org/units/Nanomolar,2518930,=,37,1,=,,IC50,nM,,1.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.3
,231269,17619273,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1(C)CCOCC1)C1(C)CCCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.16', 'le': '0.20', 'lle': '5.21', 'sei': '4.82'}",CHEMBL3645724,,CHEMBL3645724,9.00,0,http://www.openphacts.org/units/Nanomolar,2518931,=,37,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,231270,17619274,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1(C)CCOCC1)C1(C)CCCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '8.38', 'le': '0.16', 'lle': '3.09', 'sei': '4.10'}",CHEMBL3645725,,CHEMBL3645725,7.66,0,http://www.openphacts.org/units/Nanomolar,2518932,=,37,1,=,,IC50,nM,,22.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,22.0
,231271,17619275,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1CC)C1(C)CCCCC1)C1(C)CCCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.00', 'le': '0.18', 'lle': '3.02', 'sei': '4.49'}",CHEMBL3645726,,CHEMBL3645726,7.96,0,http://www.openphacts.org/units/Nanomolar,2518933,=,37,1,=,,IC50,nM,,11.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.0
,231272,17619276,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1(C)CCCCC1)C1(C)CCCCC1)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.34', 'le': '0.18', 'lle': '2.80', 'sei': '4.81'}",CHEMBL3645727,,CHEMBL3645727,8.52,0,http://www.openphacts.org/units/Nanomolar,2518934,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231273,17619277,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1[nH]c(C)c(C)c1C(C)=O)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL3639192,,2013,"{'bei': '8.86', 'le': '0.17', 'lle': '3.21', 'sei': '3.53'}",CHEMBL3645728,,CHEMBL3645728,7.19,0,http://www.openphacts.org/units/Nanomolar,2518935,=,37,1,=,,IC50,nM,,65.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,65.0
,231274,17619278,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)C,,,CHEMBL3639192,,2013,"{'bei': '10.90', 'le': '0.21', 'lle': '5.42', 'sei': '5.10'}",CHEMBL3645729,,CHEMBL3645729,9.05,0,http://www.openphacts.org/units/Nanomolar,2518936,=,37,1,=,,IC50,nM,,0.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.9
,231275,17619279,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC1CC1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CCCCN1C(C)C)C(C)(C)C)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCC[C@H]1CO,,,CHEMBL3639192,,2013,"{'bei': '6.77', 'le': '0.13', 'lle': '2.83', 'sei': '2.95'}",CHEMBL3645730,,CHEMBL3645730,5.82,0,http://www.openphacts.org/units/Nanomolar,2518937,=,37,1,=,,IC50,nM,,1500.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1500.0
,231276,17619280,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC1CC1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CC(F)(F)C1,,,CHEMBL3639192,,2013,"{'bei': '9.22', 'le': '0.18', 'lle': '4.08', 'sei': '4.57'}",CHEMBL3645731,,CHEMBL3645731,8.10,0,http://www.openphacts.org/units/Nanomolar,2518938,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231277,17619281,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)NC1CC1,,,CHEMBL3639192,,2013,"{'bei': '10.32', 'le': '0.20', 'lle': '5.55', 'sei': '3.93'}",CHEMBL3645732,,CHEMBL3645732,8.21,0,http://www.openphacts.org/units/Nanomolar,2518939,=,37,1,=,,IC50,nM,,6.2,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.2
,231278,17619282,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)NC(C)(C)C,,,CHEMBL3639192,,2013,"{'bei': '9.86', 'le': '0.19', 'lle': '4.71', 'sei': '3.83'}",CHEMBL3645733,,CHEMBL3645733,8.00,0,http://www.openphacts.org/units/Nanomolar,2518940,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231279,17619283,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '11.57', 'le': '0.22', 'lle': '6.36', 'sei': '4.61'}",CHEMBL3645734,,CHEMBL3645734,9.22,0,http://www.openphacts.org/units/Nanomolar,2518941,=,37,1,=,,IC50,nM,,0.6,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.6
,231280,17619284,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CCCl,,,CHEMBL3639192,,2013,"{'bei': '9.05', 'le': '0.18', 'lle': '4.44', 'sei': '3.76'}",CHEMBL3645735,,CHEMBL3645735,7.52,0,http://www.openphacts.org/units/Nanomolar,2518942,=,37,1,=,,IC50,nM,,30.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,30.0
,231281,17619285,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)NC(C)(C)C,,,CHEMBL3639192,,2013,"{'bei': '10.28', 'le': '0.20', 'lle': '4.37', 'sei': '4.74'}",CHEMBL3645736,,CHEMBL3645736,8.82,0,http://www.openphacts.org/units/Nanomolar,2518943,=,37,1,=,,IC50,nM,,1.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.5
,231282,17619286,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CC,,,CHEMBL3639192,,2013,"{'bei': '11.02', 'le': '0.22', 'lle': '5.28', 'sei': '5.25'}",CHEMBL3645737,,CHEMBL3645737,9.30,0,http://www.openphacts.org/units/Nanomolar,2518944,=,37,1,=,,IC50,nM,,0.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.5
,231283,17619287,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(C)CCCl,,,CHEMBL3639192,,2013,"{'bei': '10.24', 'le': '0.20', 'lle': '4.76', 'sei': '5.08'}",CHEMBL3645738,,CHEMBL3645738,9.00,0,http://www.openphacts.org/units/Nanomolar,2518945,=,37,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,231284,17619288,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)NC1CC1,,,CHEMBL3639192,,2013,"{'bei': '10.21', 'le': '0.20', 'lle': '4.78', 'sei': '4.62'}",CHEMBL3645739,,CHEMBL3645739,8.60,0,http://www.openphacts.org/units/Nanomolar,2518946,=,37,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,231285,17619289,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.51', 'le': '0.20', 'lle': '5.27', 'sei': '4.26'}",CHEMBL3645740,,CHEMBL3645740,8.52,0,http://www.openphacts.org/units/Nanomolar,2518947,=,37,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
,231286,17619290,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '10.75', 'le': '0.21', 'lle': '4.81', 'sei': '5.20'}",CHEMBL3645741,,CHEMBL3645741,9.22,0,http://www.openphacts.org/units/Nanomolar,2518948,=,37,1,=,,IC50,nM,,0.6,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.6
,231287,17619291,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)Cc1ccncc1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.73', 'le': '0.19', 'lle': '4.46', 'sei': '4.28'}",CHEMBL3645742,,CHEMBL3645742,8.00,0,http://www.openphacts.org/units/Nanomolar,2518949,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231288,17619292,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc3cc(OC)ccc3[nH]1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.68', 'le': '0.17', 'lle': '2.90', 'sei': '3.82'}",CHEMBL3645743,,CHEMBL3645743,7.60,0,http://www.openphacts.org/units/Nanomolar,2518950,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231289,17619293,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCc3ccccc3C1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.68', 'le': '0.17', 'lle': '3.64', 'sei': '4.29'}",CHEMBL3645744,,CHEMBL3645744,7.60,0,http://www.openphacts.org/units/Nanomolar,2518951,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231290,17619294,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc3ccccc3n1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.25', 'le': '0.16', 'lle': '2.40', 'sei': '3.96'}",CHEMBL3645745,,CHEMBL3645745,7.10,0,http://www.openphacts.org/units/Nanomolar,2518952,=,37,1,=,,IC50,nM,,80.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,80.0
,231291,17619295,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CC1CCCCO1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.17', 'le': '0.18', 'lle': '3.74', 'sei': '4.15'}",CHEMBL3645746,,CHEMBL3645746,7.60,0,http://www.openphacts.org/units/Nanomolar,2518953,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231292,17619296,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc(C)nn1CC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.97', 'le': '0.17', 'lle': '3.78', 'sei': '3.92'}",CHEMBL3645747,,CHEMBL3645747,7.52,0,http://www.openphacts.org/units/Nanomolar,2518954,=,37,1,=,,IC50,nM,,30.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,30.0
,231293,17619297,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc(C(C)(C)C)nn1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.13', 'le': '0.16', 'lle': '2.81', 'sei': '3.67'}",CHEMBL3645748,,CHEMBL3645748,7.05,0,http://www.openphacts.org/units/Nanomolar,2518955,=,37,1,=,,IC50,nM,,90.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,90.0
,231294,17619298,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccccc1NC)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.56', 'le': '0.17', 'lle': '2.90', 'sei': '3.84'}",CHEMBL3639446,,CHEMBL3639446,7.16,0,http://www.openphacts.org/units/Nanomolar,2518956,=,37,1,=,,IC50,nM,,70.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,70.0
,231295,17619299,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc(C)nn1C(C)(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.10', 'le': '0.16', 'lle': '2.55', 'sei': '3.66'}",CHEMBL3645749,,CHEMBL3645749,7.02,0,http://www.openphacts.org/units/Nanomolar,2518957,=,37,1,=,,IC50,nM,,95.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,95.0
,231296,17619300,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnn(-c3ccccc3)c1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.54', 'le': '0.16', 'lle': '3.06', 'sei': '3.89'}",CHEMBL3645750,,CHEMBL3645750,7.46,0,http://www.openphacts.org/units/Nanomolar,2518958,=,37,1,=,,IC50,nM,,35.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.0
,231297,17619301,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc(CC)nn1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.82', 'le': '0.17', 'lle': '3.89', 'sei': '3.85'}",CHEMBL3645751,,CHEMBL3645751,7.40,0,http://www.openphacts.org/units/Nanomolar,2518959,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231298,17619302,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)Cn1nc(C)cc1C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.57', 'le': '0.17', 'lle': '3.78', 'sei': '3.75'}",CHEMBL3645752,,CHEMBL3645752,7.19,0,http://www.openphacts.org/units/Nanomolar,2518960,=,37,1,=,,IC50,nM,,65.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,65.0
,231299,17619303,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(C)=O)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.03', 'le': '0.18', 'lle': '4.69', 'sei': '3.91'}",CHEMBL3645753,,CHEMBL3645753,7.60,0,http://www.openphacts.org/units/Nanomolar,2518961,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231300,17619304,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc3ccccc3[nH]1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.10', 'le': '0.18', 'lle': '3.01', 'sei': '4.05'}",CHEMBL3645754,,CHEMBL3645754,7.70,0,http://www.openphacts.org/units/Nanomolar,2518962,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231301,17619305,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1c[nH]c3ccccc13)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.98', 'le': '0.17', 'lle': '2.91', 'sei': '4.00'}",CHEMBL3645755,,CHEMBL3645755,7.60,0,http://www.openphacts.org/units/Nanomolar,2518963,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231302,17619306,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc3[nH]ccc3c1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.10', 'le': '0.18', 'lle': '3.01', 'sei': '4.05'}",CHEMBL3645756,,CHEMBL3645756,7.70,0,http://www.openphacts.org/units/Nanomolar,2518964,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231303,17619307,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cc3ccccc3o1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.57', 'le': '0.17', 'lle': '2.30', 'sei': '3.88'}",CHEMBL3645757,,CHEMBL3645757,7.26,0,http://www.openphacts.org/units/Nanomolar,2518965,=,37,1,=,,IC50,nM,,55.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,55.0
,231304,17619308,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc3occc3c1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.97', 'le': '0.17', 'lle': '2.64', 'sei': '4.06'}",CHEMBL3645758,,CHEMBL3645758,7.60,0,http://www.openphacts.org/units/Nanomolar,2518966,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231305,17619309,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](OC)c1ccccc1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.93', 'le': '0.17', 'lle': '3.31', 'sei': '4.15'}",CHEMBL3645759,,CHEMBL3645759,7.60,0,http://www.openphacts.org/units/Nanomolar,2518967,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,231306,17619310,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C1CCN(C(C)=O)CC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.34', 'le': '0.18', 'lle': '4.84', 'sei': '4.12'}",CHEMBL3645760,,CHEMBL3645760,8.00,0,http://www.openphacts.org/units/Nanomolar,2518968,=,37,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,231307,17619311,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1nccc3ccccc13)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.30', 'le': '0.16', 'lle': '2.36', 'sei': '3.81'}",CHEMBL3645761,,CHEMBL3645761,7.12,0,http://www.openphacts.org/units/Nanomolar,2518969,=,37,1,=,,IC50,nM,,75.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,75.0
,231308,17619312,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnc3ccccc3c1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.97', 'le': '0.17', 'lle': '2.94', 'sei': '4.12'}",CHEMBL3645762,,CHEMBL3645762,7.70,0,http://www.openphacts.org/units/Nanomolar,2518970,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231309,17619313,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccnc3ccccc13)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.62', 'le': '0.17', 'lle': '2.64', 'sei': '3.96'}",CHEMBL3645763,,CHEMBL3645763,7.40,0,http://www.openphacts.org/units/Nanomolar,2518971,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231310,17619314,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc3c(ccn3C)c1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '8.60', 'le': '0.17', 'lle': '2.70', 'sei': '4.13'}",CHEMBL3645764,,CHEMBL3645764,7.40,0,http://www.openphacts.org/units/Nanomolar,2518972,=,37,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,231311,17619315,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnc(C)cn1)C(C)CCC)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.68', 'le': '0.19', 'lle': '4.68', 'sei': '3.93'}",CHEMBL3645765,,CHEMBL3645765,7.85,0,http://www.openphacts.org/units/Nanomolar,2518973,=,37,1,=,,IC50,nM,,14.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,14.0
,231312,17619316,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '10.27', 'le': '0.20', 'lle': '5.64', 'sei': '4.57'}",CHEMBL3645766,,CHEMBL3645766,8.10,0,http://www.openphacts.org/units/Nanomolar,2518974,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,231313,17619317,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnon1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.33', 'le': '0.18', 'lle': '4.87', 'sei': '3.50'}",CHEMBL3645767,,CHEMBL3645767,7.46,0,http://www.openphacts.org/units/Nanomolar,2518975,=,37,1,=,,IC50,nM,,35.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.0
,231314,17619318,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCN(C)CC1)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N1CCCC1,,,CHEMBL3639192,,2013,"{'bei': '9.13', 'le': '0.18', 'lle': '5.56', 'sei': '4.26'}",CHEMBL3645768,,CHEMBL3645768,7.70,0,http://www.openphacts.org/units/Nanomolar,2518976,=,37,1,=,,IC50,nM,,20.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.0
,231315,17619319,[],CHEMBL3705720,"Inhibition Assay: The inhibitory activity of certain compounds against HCV NS3-4A serine protease is determined in a homogenous assay using the full-length NS3-4A protein (genotype 1a, strain HCV-1) and a commercially available internally-quenched fluorogenic peptide substrate as described by Taliani, M., et al. 1996 Anal. Biochem. 240:60-67, which is incorporated by reference in its entirety.",B,,,BAO_0000190,BAO_0000223,protein complex format,CCC1CC1(NC(=O)[C@@H]1C[C@@]2(CN1C(=O)[C@@H](NC(=O)C(NC(=O)[C@@H]1CCCCN1C(C)C)C1CCCCC1)C(C)(C)C)C(C)(C)C21CCC1)C(=O)NS(=O)(=O)N(CC)CC,,,CHEMBL3639192,,2013,"{'bei': '9.41', 'le': '0.18', 'lle': '3.47', 'sei': '4.57'}",CHEMBL3648645,,CHEMBL3648645,8.10,0,http://www.openphacts.org/units/Nanomolar,2522110,=,37,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,410878,17775694,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccccc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.82', 'le': '0.26', 'lle': '3.44', 'sei': '6.96'}",CHEMBL3920030,,CHEMBL3920030,8.49,0,http://www.openphacts.org/units/Nanomolar,2885373,=,37,1,=,,IC50,nM,,3.218,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.218
,410879,17775695,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.29', 'le': '0.24', 'lle': '2.42', 'sei': '6.23'}",CHEMBL3922869,,CHEMBL3922869,7.61,0,http://www.openphacts.org/units/Nanomolar,2885374,=,37,1,=,,IC50,nM,,24.83,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,24.83
,410880,17775696,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(c3cccc(F)c3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.44', 'le': '0.26', 'lle': '3.13', 'sei': '6.81'}",CHEMBL3954316,,CHEMBL3954316,8.32,0,http://www.openphacts.org/units/Nanomolar,2885375,=,37,1,=,,IC50,nM,,4.826,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.826
,410881,17775697,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(CCc3ccccc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.77', 'le': '0.22', 'lle': '2.31', 'sei': '6.06'}",CHEMBL3963867,,CHEMBL3963867,7.40,0,http://www.openphacts.org/units/Nanomolar,2885376,=,37,1,=,,IC50,nM,,39.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,39.9
,410882,17775698,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(OC)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.21', 'le': '0.25', 'lle': '3.45', 'sei': '6.49'}",CHEMBL3957232,,CHEMBL3957232,8.52,0,http://www.openphacts.org/units/Nanomolar,2885377,=,37,1,=,,IC50,nM,,3.055,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.055
,410883,17775699,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.52', 'le': '0.26', 'lle': '3.37', 'sei': '7.01'}",CHEMBL3955887,,CHEMBL3955887,8.56,0,http://www.openphacts.org/units/Nanomolar,2885378,=,37,1,=,,IC50,nM,,2.782,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.782
,410884,17775700,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3cccc(F)c3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.96', 'le': '0.27', 'lle': '3.64', 'sei': '7.23'}",CHEMBL3901368,,CHEMBL3901368,8.83,0,http://www.openphacts.org/units/Nanomolar,2885379,=,37,1,=,,IC50,nM,,1.481,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.481
,410885,17775701,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccccc3F)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.01', 'le': '0.25', 'lle': '3.04', 'sei': '6.74'}",CHEMBL3967005,,CHEMBL3967005,8.23,0,http://www.openphacts.org/units/Nanomolar,2885380,=,37,1,=,,IC50,nM,,5.873,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.873
,410886,17775702,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(C#N)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.66', 'le': '0.24', 'lle': '3.18', 'sei': '5.55'}",CHEMBL3895714,,CHEMBL3895714,8.10,0,http://www.openphacts.org/units/Nanomolar,2885381,=,37,1,=,,IC50,nM,,8.032,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.032
,410887,17775703,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(Cl)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.04', 'le': '0.28', 'lle': '3.41', 'sei': '7.47'}",CHEMBL3949455,,CHEMBL3949455,9.12,0,http://www.openphacts.org/units/Nanomolar,2885382,=,37,1,=,,IC50,nM,,0.7678,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.7678
,410888,17775704,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cn3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.33', 'le': '0.24', 'lle': '3.23', 'sei': '5.79'}",CHEMBL3975365,,CHEMBL3975365,7.82,0,http://www.openphacts.org/units/Nanomolar,2885383,=,37,1,=,,IC50,nM,,15.32,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.32
,410889,17775705,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(cn3)OCN(Cc3ccc(F)cc3)C4=O)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.89', 'le': '0.25', 'lle': '2.96', 'sei': '6.68'}",CHEMBL3932292,,CHEMBL3932292,8.15,0,http://www.openphacts.org/units/Nanomolar,2885384,=,37,1,=,,IC50,nM,,7.019,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.019
,410890,17775706,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)N(Cc3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.58', 'le': '0.26', 'lle': '3.40', 'sei': '7.04'}",CHEMBL3986806,,CHEMBL3986806,8.59,0,http://www.openphacts.org/units/Nanomolar,2885385,=,37,1,=,,IC50,nM,,2.551,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.551
,410891,17775707,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4oc(=O)n(Cc5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '9.84', 'le': '0.19', 'lle': '1.85', 'sei': '4.40'}",CHEMBL3925629,,CHEMBL3925629,6.36,0,http://www.openphacts.org/units/Nanomolar,2885386,=,37,1,=,,IC50,nM,,434.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,434.9
,410892,17775708,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)NC(c3cccs3)N4)cc12,,,CHEMBL3886778,,2016,"{'bei': '10.57', 'le': '0.21', 'lle': '1.43', 'sei': '4.79'}",CHEMBL3966786,,CHEMBL3966786,6.40,0,http://www.openphacts.org/units/Nanomolar,2885387,=,37,1,=,,IC50,nM,,395.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,395.4
,410893,17775709,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)NC(C3CC3)N4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.23', 'le': '0.24', 'lle': '2.94', 'sei': '5.16'}",CHEMBL3904432,,CHEMBL3904432,6.89,0,http://www.openphacts.org/units/Nanomolar,2885388,=,37,1,=,,IC50,nM,,128.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,128.4
,410894,17775710,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4nc(-c5cccc(F)c5)[nH]c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.03', 'le': '0.21', 'lle': '1.69', 'sei': '4.91'}",CHEMBL3972082,,CHEMBL3972082,6.79,0,http://www.openphacts.org/units/Nanomolar,2885389,=,37,1,=,,IC50,nM,,161.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,161.5
,410895,17775711,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)NC(c3cccc(F)c3)NC4=O)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.92', 'le': '0.25', 'lle': '2.93', 'sei': '5.97'}",CHEMBL3910003,,CHEMBL3910003,7.98,0,http://www.openphacts.org/units/Nanomolar,2885390,=,37,1,=,,IC50,nM,,10.51,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.51
,410896,17775712,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)N(Cc3ccc(F)cc3)CN4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.92', 'le': '0.27', 'lle': '3.58', 'sei': '7.04'}",CHEMBL3941710,,CHEMBL3941710,8.80,0,http://www.openphacts.org/units/Nanomolar,2885391,=,37,1,=,,IC50,nM,,1.601,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.601
,410897,17775713,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(-c5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.92', 'le': '0.26', 'lle': '2.95', 'sei': '7.25'}",CHEMBL3969256,,CHEMBL3969256,8.31,0,http://www.openphacts.org/units/Nanomolar,2885392,=,37,1,=,,IC50,nM,,4.936,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.936
,410898,17775714,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5ccccc5F)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.32', 'le': '0.25', 'lle': '3.31', 'sei': '6.44'}",CHEMBL3894421,,CHEMBL3894421,8.20,0,http://www.openphacts.org/units/Nanomolar,2885393,=,37,1,=,,IC50,nM,,6.321,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.321
,410899,17775715,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.65', 'le': '0.24', 'lle': '2.90', 'sei': '6.11'}",CHEMBL3945713,,CHEMBL3945713,7.79,0,http://www.openphacts.org/units/Nanomolar,2885394,=,37,1,=,,IC50,nM,,16.24,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,16.24
,410900,17775716,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5cccc(F)c5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.65', 'le': '0.26', 'lle': '3.51', 'sei': '6.59'}",CHEMBL3974309,,CHEMBL3974309,8.40,0,http://www.openphacts.org/units/Nanomolar,2885395,=,37,1,=,,IC50,nM,,3.978,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.978
,410901,17775717,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.64', 'le': '0.26', 'lle': '3.64', 'sei': '6.74'}",CHEMBL3938855,,CHEMBL3938855,8.59,0,http://www.openphacts.org/units/Nanomolar,2885396,=,37,1,=,,IC50,nM,,2.588,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.588
,410902,17775718,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.10', 'le': '0.23', 'lle': '2.28', 'sei': '6.11'}",CHEMBL4115262,,CHEMBL4115262,7.79,0,http://www.openphacts.org/units/Nanomolar,2885397,=,37,1,=,,IC50,nM,,16.33,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,16.33
,410903,17775719,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(-c5ccccc5F)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.94', 'le': '0.23', 'lle': '2.46', 'sei': '5.77'}",CHEMBL3982540,,CHEMBL3982540,7.35,0,http://www.openphacts.org/units/Nanomolar,2885398,=,37,1,=,,IC50,nM,,44.65,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,44.65
,410904,17775720,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4nc[nH]c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.35', 'le': '0.24', 'lle': '3.76', 'sei': '4.27'}",CHEMBL3960822,,CHEMBL3960822,6.45,0,http://www.openphacts.org/units/Nanomolar,2885399,=,37,1,=,,IC50,nM,,352.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,352.9
,410905,17775721,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5cccc(F)c5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.47', 'le': '0.26', 'lle': '4.01', 'sei': '5.92'}",CHEMBL3959793,,CHEMBL3959793,8.30,0,http://www.openphacts.org/units/Nanomolar,2885400,=,37,1,=,,IC50,nM,,4.957,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.957
,410906,17775722,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)C4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.20', 'le': '0.25', 'lle': '2.79', 'sei': '7.22'}",CHEMBL3974920,,CHEMBL3974920,8.14,0,http://www.openphacts.org/units/Nanomolar,2885401,=,37,1,=,,IC50,nM,,7.211,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.211
,410907,17775723,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(C(C)c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.93', 'le': '0.27', 'lle': '3.26', 'sei': '7.38'}",CHEMBL3947642,,CHEMBL3947642,9.01,0,http://www.openphacts.org/units/Nanomolar,2885402,=,37,1,=,,IC50,nM,,0.9806,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.9806
,410908,17775724,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(C(C)c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.41', 'le': '0.22', 'lle': '1.63', 'sei': '6.05'}",CHEMBL3947642,,CHEMBL3947642,7.38,0,http://www.openphacts.org/units/Nanomolar,2885403,=,37,1,=,,IC50,nM,,41.78,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,41.78
,410909,17775725,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc4c(n3)C(=O)N(C(C)(C)c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.11', 'le': '0.20', 'lle': '-0.38', 'sei': '7.26'}",CHEMBL3913311,,CHEMBL3913311,6.15,0,http://www.openphacts.org/units/Nanomolar,2885404,=,37,1,=,,IC50,nM,,708.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,708.3
,410910,17775726,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '9.61', 'le': '0.18', 'lle': '-0.74', 'sei': '5.96'}",CHEMBL3936639,,CHEMBL3936639,5.05,0,http://www.openphacts.org/units/Nanomolar,2885405,=,37,1,=,,IC50,nM,,8928.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8928.0
,410911,17775727,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(c3)C(=O)N(Cc3ccc(F)cc3)CC4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.77', 'le': '0.26', 'lle': '2.67', 'sei': '8.67'}",CHEMBL3949927,,CHEMBL3949927,8.67,0,http://www.openphacts.org/units/Nanomolar,2885406,=,37,1,=,,IC50,nM,,2.147,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.147
,410912,17775728,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CC4)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.22', 'le': '0.27', 'lle': '3.58', 'sei': '7.95'}",CHEMBL3890470,,CHEMBL3890470,8.97,0,http://www.openphacts.org/units/Nanomolar,2885407,=,37,1,=,,IC50,nM,,1.081,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.081
,410913,17775729,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CC4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.58', 'le': '0.25', 'lle': '1.11', 'sei': '9.43'}",CHEMBL3913046,,CHEMBL3913046,7.11,0,http://www.openphacts.org/units/Nanomolar,2885408,=,37,1,=,,IC50,nM,,77.35,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,77.35
,410914,17775730,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ccn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.12', 'le': '0.27', 'lle': '2.70', 'sei': '8.72'}",CHEMBL3982915,,CHEMBL3982915,8.86,0,http://www.openphacts.org/units/Nanomolar,2885409,=,37,1,=,,IC50,nM,,1.375,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.375
,410915,17775731,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@H](COC)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.46', 'le': '0.24', 'lle': '3.25', 'sei': '6.14'}",CHEMBL4115427,,CHEMBL4115427,8.39,0,http://www.openphacts.org/units/Nanomolar,2885410,=,37,1,=,,IC50,nM,,4.035,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.035
,410916,17775732,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@H](CO)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.44', 'le': '0.24', 'lle': '3.72', 'sei': '5.56'}",CHEMBL4110077,,CHEMBL4110077,8.21,0,http://www.openphacts.org/units/Nanomolar,2885411,=,37,1,=,,IC50,nM,,6.19,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.19
,410917,17775733,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@@H](COC)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.49', 'le': '0.22', 'lle': '2.60', 'sei': '5.67'}",CHEMBL3955209,,CHEMBL3955209,7.74,0,http://www.openphacts.org/units/Nanomolar,2885412,=,37,1,=,,IC50,nM,,18.13,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,18.13
,410918,17775734,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.12', 'le': '0.25', 'lle': '3.21', 'sei': '6.30'}",CHEMBL3927591,,CHEMBL3927591,8.02,0,http://www.openphacts.org/units/Nanomolar,2885413,=,37,1,=,,IC50,nM,,9.482,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.482
,410919,17775735,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(C(CO)c5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.19', 'le': '0.23', 'lle': '3.47', 'sei': '5.30'}",CHEMBL3968491,,CHEMBL3968491,7.82,0,http://www.openphacts.org/units/Nanomolar,2885414,=,37,1,=,,IC50,nM,,15.08,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.08
,410920,17775736,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.10', 'le': '0.25', 'lle': '3.30', 'sei': '6.48'}",CHEMBL3960796,,CHEMBL3960796,8.25,0,http://www.openphacts.org/units/Nanomolar,2885415,=,37,1,=,,IC50,nM,,5.619,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.619
,410921,17775737,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.58', 'le': '0.22', 'lle': '1.95', 'sei': '5.85'}",CHEMBL3936097,,CHEMBL3936097,7.46,0,http://www.openphacts.org/units/Nanomolar,2885416,=,37,1,=,,IC50,nM,,35.03,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.03
,410922,17775738,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.61', 'le': '0.24', 'lle': '2.61', 'sei': '6.37'}",CHEMBL4109706,,CHEMBL4109706,8.12,0,http://www.openphacts.org/units/Nanomolar,2885417,=,37,1,=,,IC50,nM,,7.646,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.646
,410923,17775739,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccc(F)cc5OC)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.67', 'le': '0.22', 'lle': '2.74', 'sei': '5.63'}",CHEMBL3927052,,CHEMBL3927052,7.70,0,http://www.openphacts.org/units/Nanomolar,2885418,=,37,1,=,,IC50,nM,,20.16,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.16
,410924,17775740,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccc(F)cn5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.94', 'le': '0.25', 'lle': '3.81', 'sei': '5.82'}",CHEMBL3964459,,CHEMBL3964459,8.16,0,http://www.openphacts.org/units/Nanomolar,2885419,=,37,1,=,,IC50,nM,,6.928,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.928
,410925,17775741,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(Cc5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.44', 'le': '0.25', 'lle': '2.78', 'sei': '7.16'}",CHEMBL3949897,,CHEMBL3949897,8.20,0,http://www.openphacts.org/units/Nanomolar,2885420,=,37,1,=,,IC50,nM,,6.245,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.245
,410926,17775742,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.22', 'le': '0.25', 'lle': '2.38', 'sei': '7.42'}",CHEMBL4109293,,CHEMBL4109293,8.50,0,http://www.openphacts.org/units/Nanomolar,2885421,=,37,1,=,,IC50,nM,,3.176,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.176
,410927,17775743,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(Cc5ccc(F)cc5OC)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.22', 'le': '0.23', 'lle': '2.48', 'sei': '6.50'}",CHEMBL3898973,,CHEMBL3898973,8.05,0,http://www.openphacts.org/units/Nanomolar,2885422,=,37,1,=,,IC50,nM,,8.978,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.978
,410928,17775744,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(Cc5ccc(F)cn5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.02', 'le': '0.25', 'lle': '3.25', 'sei': '6.43'}",CHEMBL3889513,,CHEMBL3889513,8.20,0,http://www.openphacts.org/units/Nanomolar,2885423,=,37,1,=,,IC50,nM,,6.369,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.369
,410929,17775745,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(COC)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.77', 'le': '0.24', 'lle': '2.88', 'sei': '6.94'}",CHEMBL3930991,,CHEMBL3930991,8.59,0,http://www.openphacts.org/units/Nanomolar,2885424,=,37,1,=,,IC50,nM,,2.566,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.566
,410930,17775746,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(CNC(C)=O)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.33', 'le': '0.24', 'lle': '3.44', 'sei': '6.01'}",CHEMBL3958500,,CHEMBL3958500,8.63,0,http://www.openphacts.org/units/Nanomolar,2885425,=,37,1,=,,IC50,nM,,2.343,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.343
,410931,17775747,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.56', 'le': '0.26', 'lle': '2.84', 'sei': '7.61'}",CHEMBL3961836,,CHEMBL3961836,8.71,0,http://www.openphacts.org/units/Nanomolar,2885426,=,37,1,=,,IC50,nM,,1.934,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.934
,410932,17775748,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.21', 'le': '0.23', 'lle': '1.59', 'sei': '7.00'}",CHEMBL4110048,,CHEMBL4110048,8.02,0,http://www.openphacts.org/units/Nanomolar,2885427,=,37,1,=,,IC50,nM,,9.65,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.65
,410933,17775749,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5OC)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.32', 'le': '0.22', 'lle': '2.35', 'sei': '5.58'}",CHEMBL3972861,,CHEMBL3972861,7.62,0,http://www.openphacts.org/units/Nanomolar,2885428,=,37,1,=,,IC50,nM,,23.72,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,23.72
,410934,17775750,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5F)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.67', 'le': '0.24', 'lle': '2.98', 'sei': '6.58'}",CHEMBL3946725,,CHEMBL3946725,8.38,0,http://www.openphacts.org/units/Nanomolar,2885429,=,37,1,=,,IC50,nM,,4.122,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.122
,410935,17775751,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@@H](COC)c5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.68', 'le': '0.22', 'lle': '2.58', 'sei': '5.88'}",CHEMBL3947778,,CHEMBL3947778,8.03,0,http://www.openphacts.org/units/Nanomolar,2885430,=,37,1,=,,IC50,nM,,9.279,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.279
,410936,17775752,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@H](CCO)c5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.83', 'le': '0.23', 'lle': '2.95', 'sei': '5.51'}",CHEMBL4109025,,CHEMBL4109025,8.14,0,http://www.openphacts.org/units/Nanomolar,2885431,=,37,1,=,,IC50,nM,,7.286,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.286
,410937,17775753,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@H](COC)c5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.07', 'le': '0.23', 'lle': '2.85', 'sei': '6.08'}",CHEMBL4107186,,CHEMBL4107186,8.30,0,http://www.openphacts.org/units/Nanomolar,2885432,=,37,1,=,,IC50,nM,,4.971,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.971
,410938,17775754,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.51', 'le': '0.26', 'lle': '3.44', 'sei': '6.83'}",CHEMBL3925436,,CHEMBL3925436,8.70,0,http://www.openphacts.org/units/Nanomolar,2885433,=,37,1,=,,IC50,nM,,2.004,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.004
,410939,17775755,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc(OC)c4nc(C)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.16', 'le': '0.23', 'lle': '2.30', 'sei': '6.61'}",CHEMBL3983489,,CHEMBL3983489,8.18,0,http://www.openphacts.org/units/Nanomolar,2885434,=,37,1,=,,IC50,nM,,6.645,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.645
,410940,17775756,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(=O)n(Cc5ccc(F)cc5)nnc4cc3F)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.27', 'le': '0.24', 'lle': '2.86', 'sei': '6.24'}",CHEMBL3942127,,CHEMBL3942127,7.95,0,http://www.openphacts.org/units/Nanomolar,2885435,=,37,1,=,,IC50,nM,,11.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.3
,410941,17775757,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc(OC)c4nnn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.82', 'le': '0.25', 'lle': '3.50', 'sei': '6.19'}",CHEMBL3961240,,CHEMBL3961240,8.46,0,http://www.openphacts.org/units/Nanomolar,2885436,=,37,1,=,,IC50,nM,,3.486,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.486
,410942,17775758,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(=O)n(Cc5ccc(F)cc5)nnc4cc3C)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.53', 'le': '0.24', 'lle': '2.80', 'sei': '6.33'}",CHEMBL3986495,,CHEMBL3986495,8.06,0,http://www.openphacts.org/units/Nanomolar,2885437,=,37,1,=,,IC50,nM,,8.621,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.621
,410943,17775759,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(=O)n(Cc5ccc(F)cc5)nnc4cc3Cl)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.95', 'le': '0.24', 'lle': '2.33', 'sei': '6.23'}",CHEMBL3949157,,CHEMBL3949157,7.94,0,http://www.openphacts.org/units/Nanomolar,2885438,=,37,1,=,,IC50,nM,,11.59,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.59
,410944,17775760,[],CHEMBL3888610,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc(C)c4nnn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.31', 'le': '0.24', 'lle': '2.66', 'sei': '6.22'}",CHEMBL3978278,,CHEMBL3978278,7.92,0,http://www.openphacts.org/units/Nanomolar,2885439,=,37,1,=,,IC50,nM,,11.94,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.94
,410945,17775761,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccccc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.01', 'le': '0.27', 'lle': '3.56', 'sei': '7.06'}",CHEMBL3920030,,CHEMBL3920030,8.61,0,http://www.openphacts.org/units/Nanomolar,2885373,=,37,1,=,,IC50,nM,,2.435,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.435
,410946,17775762,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.70', 'le': '0.26', 'lle': '3.29', 'sei': '6.94'}",CHEMBL3922869,,CHEMBL3922869,8.48,0,http://www.openphacts.org/units/Nanomolar,2885374,=,37,1,=,,IC50,nM,,3.341,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.341
,410947,17775763,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(c3cccc(F)c3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.82', 'le': '0.27', 'lle': '3.36', 'sei': '7.00'}",CHEMBL3954316,,CHEMBL3954316,8.55,0,http://www.openphacts.org/units/Nanomolar,2885375,=,37,1,=,,IC50,nM,,2.842,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.842
,410948,17775764,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(CCc3ccccc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.43', 'le': '0.24', 'lle': '2.73', 'sei': '6.41'}",CHEMBL3963867,,CHEMBL3963867,7.82,0,http://www.openphacts.org/units/Nanomolar,2885376,=,37,1,=,,IC50,nM,,15.22,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.22
,410949,17775765,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(OC)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.65', 'le': '0.26', 'lle': '3.74', 'sei': '6.70'}",CHEMBL3957232,,CHEMBL3957232,8.80,0,http://www.openphacts.org/units/Nanomolar,2885377,=,37,1,=,,IC50,nM,,1.592,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.592
,410950,17775766,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.77', 'le': '0.26', 'lle': '3.52', 'sei': '7.14'}",CHEMBL3955887,,CHEMBL3955887,8.71,0,http://www.openphacts.org/units/Nanomolar,2885378,=,37,1,=,,IC50,nM,,1.933,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.933
,410951,17775767,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3cccc(F)c3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.18', 'le': '0.27', 'lle': '3.78', 'sei': '7.35'}",CHEMBL3901368,,CHEMBL3901368,8.97,0,http://www.openphacts.org/units/Nanomolar,2885379,=,37,1,=,,IC50,nM,,1.063,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.063
,410952,17775768,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccccc3F)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.57', 'le': '0.26', 'lle': '3.39', 'sei': '7.03'}",CHEMBL3967005,,CHEMBL3967005,8.58,0,http://www.openphacts.org/units/Nanomolar,2885380,=,37,1,=,,IC50,nM,,2.618,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.618
,410953,17775769,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(C#N)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.14', 'le': '0.25', 'lle': '3.49', 'sei': '5.76'}",CHEMBL3895714,,CHEMBL3895714,8.41,0,http://www.openphacts.org/units/Nanomolar,2885381,=,37,1,=,,IC50,nM,,3.912,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.912
,410954,17775770,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(Cl)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.48', 'le': '0.27', 'lle': '3.05', 'sei': '7.17'}",CHEMBL3949455,,CHEMBL3949455,8.75,0,http://www.openphacts.org/units/Nanomolar,2885382,=,37,1,=,,IC50,nM,,1.79,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.79
,410955,17775771,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cn3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.81', 'le': '0.25', 'lle': '3.53', 'sei': '6.01'}",CHEMBL3975365,,CHEMBL3975365,8.12,0,http://www.openphacts.org/units/Nanomolar,2885383,=,37,1,=,,IC50,nM,,7.68,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.68
,410956,17775772,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(cn3)OCN(Cc3ccc(F)cc3)C4=O)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.48', 'le': '0.26', 'lle': '3.34', 'sei': '6.99'}",CHEMBL3932292,,CHEMBL3932292,8.53,0,http://www.openphacts.org/units/Nanomolar,2885384,=,37,1,=,,IC50,nM,,2.953,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.953
,410957,17775773,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)N(Cc3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.73', 'le': '0.26', 'lle': '3.50', 'sei': '7.12'}",CHEMBL3986806,,CHEMBL3986806,8.69,0,http://www.openphacts.org/units/Nanomolar,2885385,=,37,1,=,,IC50,nM,,2.059,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.059
,410958,17775774,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4oc(=O)n(Cc5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.51', 'le': '0.22', 'lle': '2.93', 'sei': '5.14'}",CHEMBL3925629,,CHEMBL3925629,7.45,0,http://www.openphacts.org/units/Nanomolar,2885386,=,37,1,=,,IC50,nM,,35.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.9
,410959,17775775,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)NC(c3cccs3)N4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.23', 'le': '0.24', 'lle': '2.44', 'sei': '5.54'}",CHEMBL3966786,,CHEMBL3966786,7.41,0,http://www.openphacts.org/units/Nanomolar,2885387,=,37,1,=,,IC50,nM,,39.17,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,39.17
,410960,17775776,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)NC(C3CC3)N4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.14', 'le': '0.25', 'lle': '3.46', 'sei': '5.54'}",CHEMBL3904432,,CHEMBL3904432,7.41,0,http://www.openphacts.org/units/Nanomolar,2885388,=,37,1,=,,IC50,nM,,39.19,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,39.19
,410961,17775777,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4nc(-c5cccc(F)c5)[nH]c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.88', 'le': '0.23', 'lle': '2.21', 'sei': '5.29'}",CHEMBL3972082,,CHEMBL3972082,7.31,0,http://www.openphacts.org/units/Nanomolar,2885389,=,37,1,=,,IC50,nM,,48.53,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,48.53
,410962,17775778,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)NC(c3cccc(F)c3)NC4=O)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.64', 'le': '0.26', 'lle': '3.38', 'sei': '6.31'}",CHEMBL3910003,,CHEMBL3910003,8.43,0,http://www.openphacts.org/units/Nanomolar,2885390,=,37,1,=,,IC50,nM,,3.737,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.737
,410963,17775779,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4c(c3)C(=O)N(Cc3ccc(F)cc3)CN4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.86', 'le': '0.27', 'lle': '3.54', 'sei': '7.01'}",CHEMBL3941710,,CHEMBL3941710,8.76,0,http://www.openphacts.org/units/Nanomolar,2885391,=,37,1,=,,IC50,nM,,1.747,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.747
,410964,17775780,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(-c5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.34', 'le': '0.27', 'lle': '3.19', 'sei': '7.47'}",CHEMBL3969256,,CHEMBL3969256,8.55,0,http://www.openphacts.org/units/Nanomolar,2885392,=,37,1,=,,IC50,nM,,2.794,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.794
,410965,17775781,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5ccccc5F)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.97', 'le': '0.27', 'lle': '3.71', 'sei': '6.75'}",CHEMBL3894421,,CHEMBL3894421,8.60,0,http://www.openphacts.org/units/Nanomolar,2885393,=,37,1,=,,IC50,nM,,2.509,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.509
,410966,17775782,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.62', 'le': '0.26', 'lle': '3.49', 'sei': '6.58'}",CHEMBL3945713,,CHEMBL3945713,8.38,0,http://www.openphacts.org/units/Nanomolar,2885394,=,37,1,=,,IC50,nM,,4.123,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.123
,410967,17775783,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5cccc(F)c5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.79', 'le': '0.26', 'lle': '3.60', 'sei': '6.66'}",CHEMBL3974309,,CHEMBL3974309,8.49,0,http://www.openphacts.org/units/Nanomolar,2885395,=,37,1,=,,IC50,nM,,3.24,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.24
,410968,17775784,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.64', 'le': '0.26', 'lle': '3.64', 'sei': '6.74'}",CHEMBL3938855,,CHEMBL3938855,8.59,0,http://www.openphacts.org/units/Nanomolar,2885396,=,37,1,=,,IC50,nM,,2.571,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.571
,410969,17775785,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.31', 'le': '0.24', 'lle': '2.41', 'sei': '6.22'}",CHEMBL4115262,,CHEMBL4115262,7.92,0,http://www.openphacts.org/units/Nanomolar,2885397,=,37,1,=,,IC50,nM,,11.89,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.89
,410970,17775786,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(-c5ccccc5F)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.37', 'le': '0.26', 'lle': '3.34', 'sei': '6.46'}",CHEMBL3982540,,CHEMBL3982540,8.23,0,http://www.openphacts.org/units/Nanomolar,2885398,=,37,1,=,,IC50,nM,,5.887,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.887
,410971,17775787,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4nc[nH]c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.95', 'le': '0.23', 'lle': '3.56', 'sei': '4.13'}",CHEMBL3960822,,CHEMBL3960822,6.25,0,http://www.openphacts.org/units/Nanomolar,2885399,=,37,1,=,,IC50,nM,,567.7,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,567.7
,410972,17775788,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cnc4ncn(-c5cccc(F)c5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.59', 'le': '0.26', 'lle': '4.09', 'sei': '5.97'}",CHEMBL3959793,,CHEMBL3959793,8.38,0,http://www.openphacts.org/units/Nanomolar,2885400,=,37,1,=,,IC50,nM,,4.17,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.17
,410973,17775789,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)C4)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.68', 'le': '0.28', 'lle': '3.70', 'sei': '8.02'}",CHEMBL3974920,,CHEMBL3974920,9.05,0,http://www.openphacts.org/units/Nanomolar,2885401,=,37,1,=,,IC50,nM,,0.8856,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.8856
,410974,17775790,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(C(C)c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.38', 'le': '0.26', 'lle': '2.90', 'sei': '7.09'}",CHEMBL3947642,,CHEMBL3947642,8.65,0,http://www.openphacts.org/units/Nanomolar,2885402,=,37,1,=,,IC50,nM,,2.227,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.227
,410975,17775791,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(C(C)c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.22', 'le': '0.23', 'lle': '2.15', 'sei': '6.48'}",CHEMBL3947642,,CHEMBL3947642,7.90,0,http://www.openphacts.org/units/Nanomolar,2885403,=,37,1,=,,IC50,nM,,12.49,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,12.49
,410976,17775792,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc4c(n3)C(=O)N(C(C)(C)c3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '10.43', 'le': '0.19', 'lle': '-0.76', 'sei': '6.82'}",CHEMBL3913311,,CHEMBL3913311,5.77,0,http://www.openphacts.org/units/Nanomolar,2885404,=,37,1,=,,IC50,nM,,1692.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1692.0
,410977,17775793,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CO4)cc12,,,CHEMBL3886778,,2016,"{'bei': '9.48', 'le': '0.17', 'lle': '-0.81', 'sei': '5.88'}",CHEMBL3936639,,CHEMBL3936639,4.98,0,http://www.openphacts.org/units/Nanomolar,2885405,=,37,1,=,,IC50,nM,,10430.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10430.0
,410978,17775794,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(c3)C(=O)N(Cc3ccc(F)cc3)CC4)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.92', 'le': '0.27', 'lle': '2.77', 'sei': '8.77'}",CHEMBL3949927,,CHEMBL3949927,8.77,0,http://www.openphacts.org/units/Nanomolar,2885406,=,37,1,=,,IC50,nM,,1.709,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.709
,410979,17775795,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CC4)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.71', 'le': '0.28', 'lle': '3.89', 'sei': '8.22'}",CHEMBL3890470,,CHEMBL3890470,9.28,0,http://www.openphacts.org/units/Nanomolar,2885407,=,37,1,=,,IC50,nM,,0.527,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.527
,410980,17775796,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2ccc(-c3ccc4c(n3)C(=O)N(Cc3ccc(F)cc3)CC4)cc12,,,CHEMBL3886778,,2016,"{'bei': '15.17', 'le': '0.28', 'lle': '1.94', 'sei': '10.53'}",CHEMBL3913046,,CHEMBL3913046,7.94,0,http://www.openphacts.org/units/Nanomolar,2885408,=,37,1,=,,IC50,nM,,11.42,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.42
,410981,17775797,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ccn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '14.25', 'le': '0.27', 'lle': '2.78', 'sei': '8.80'}",CHEMBL3982915,,CHEMBL3982915,8.94,0,http://www.openphacts.org/units/Nanomolar,2885409,=,37,1,=,,IC50,nM,,1.139,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.139
,410982,17775798,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@H](COC)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.92', 'le': '0.23', 'lle': '2.89', 'sei': '5.88'}",CHEMBL4115427,,CHEMBL4115427,8.03,0,http://www.openphacts.org/units/Nanomolar,2885410,=,37,1,=,,IC50,nM,,9.268,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.268
,410983,17775799,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@H](CO)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.19', 'le': '0.23', 'lle': '3.55', 'sei': '5.45'}",CHEMBL4110077,,CHEMBL4110077,8.04,0,http://www.openphacts.org/units/Nanomolar,2885411,=,37,1,=,,IC50,nM,,9.029,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.029
,410984,17775800,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@@H](COC)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.56', 'le': '0.22', 'lle': '2.65', 'sei': '5.70'}",CHEMBL3955209,,CHEMBL3955209,7.79,0,http://www.openphacts.org/units/Nanomolar,2885412,=,37,1,=,,IC50,nM,,16.22,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,16.22
,410985,17775801,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.11', 'le': '0.25', 'lle': '3.21', 'sei': '6.30'}",CHEMBL3927591,,CHEMBL3927591,8.02,0,http://www.openphacts.org/units/Nanomolar,2885413,=,37,1,=,,IC50,nM,,9.549,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.549
,410986,17775802,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(C(CO)c5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.49', 'le': '0.24', 'lle': '3.67', 'sei': '5.43'}",CHEMBL3968491,,CHEMBL3968491,8.02,0,http://www.openphacts.org/units/Nanomolar,2885414,=,37,1,=,,IC50,nM,,9.659,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.659
,410987,17775803,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.67', 'le': '0.24', 'lle': '3.03', 'sei': '6.26'}",CHEMBL3960796,,CHEMBL3960796,7.98,0,http://www.openphacts.org/units/Nanomolar,2885415,=,37,1,=,,IC50,nM,,10.53,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.53
,410988,17775804,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.05', 'le': '0.23', 'lle': '2.25', 'sei': '6.09'}",CHEMBL3936097,,CHEMBL3936097,7.76,0,http://www.openphacts.org/units/Nanomolar,2885416,=,37,1,=,,IC50,nM,,17.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,17.5
,410989,17775805,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.42', 'le': '0.24', 'lle': '2.48', 'sei': '6.27'}",CHEMBL4109706,,CHEMBL4109706,7.99,0,http://www.openphacts.org/units/Nanomolar,2885417,=,37,1,=,,IC50,nM,,10.17,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.17
,410990,17775806,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccc(F)cc5OC)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.65', 'le': '0.22', 'lle': '2.73', 'sei': '5.62'}",CHEMBL3927052,,CHEMBL3927052,7.68,0,http://www.openphacts.org/units/Nanomolar,2885418,=,37,1,=,,IC50,nM,,20.64,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,20.64
,410991,17775807,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nnn(Cc5ccc(F)cn5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.04', 'le': '0.25', 'lle': '3.87', 'sei': '5.86'}",CHEMBL3964459,,CHEMBL3964459,8.22,0,http://www.openphacts.org/units/Nanomolar,2885419,=,37,1,=,,IC50,nM,,5.971,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.971
,410992,17775808,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(Cc5ccccc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.09', 'le': '0.25', 'lle': '2.57', 'sei': '6.98'}",CHEMBL3949897,,CHEMBL3949897,7.99,0,http://www.openphacts.org/units/Nanomolar,2885420,=,37,1,=,,IC50,nM,,10.19,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.19
,410993,17775809,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.03', 'le': '0.25', 'lle': '2.25', 'sei': '7.31'}",CHEMBL4109293,,CHEMBL4109293,8.37,0,http://www.openphacts.org/units/Nanomolar,2885421,=,37,1,=,,IC50,nM,,4.227,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.227
,410994,17775810,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(Cc5ccc(F)cc5OC)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.10', 'le': '0.25', 'lle': '3.06', 'sei': '6.97'}",CHEMBL3898973,,CHEMBL3898973,8.63,0,http://www.openphacts.org/units/Nanomolar,2885422,=,37,1,=,,IC50,nM,,2.351,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.351
,410995,17775811,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4ncn(Cc5ccc(F)cn5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.78', 'le': '0.26', 'lle': '3.73', 'sei': '6.81'}",CHEMBL3889513,,CHEMBL3889513,8.68,0,http://www.openphacts.org/units/Nanomolar,2885423,=,37,1,=,,IC50,nM,,2.112,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.112
,410996,17775812,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(COC)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.80', 'le': '0.25', 'lle': '2.90', 'sei': '6.96'}",CHEMBL3930991,,CHEMBL3930991,8.61,0,http://www.openphacts.org/units/Nanomolar,2885424,=,37,1,=,,IC50,nM,,2.45,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.45
,410997,17775813,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(CNC(C)=O)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.24', 'le': '0.23', 'lle': '3.37', 'sei': '5.96'}",CHEMBL3958500,,CHEMBL3958500,8.56,0,http://www.openphacts.org/units/Nanomolar,2885425,=,37,1,=,,IC50,nM,,2.725,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.725
,410998,17775814,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.41', 'le': '0.26', 'lle': '2.75', 'sei': '7.52'}",CHEMBL3961836,,CHEMBL3961836,8.62,0,http://www.openphacts.org/units/Nanomolar,2885426,=,37,1,=,,IC50,nM,,2.421,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.421
,410999,17775815,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@H](C)c5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.19', 'le': '0.23', 'lle': '1.58', 'sei': '6.99'}",CHEMBL4110048,,CHEMBL4110048,8.01,0,http://www.openphacts.org/units/Nanomolar,2885427,=,37,1,=,,IC50,nM,,9.816,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.816
,411000,17775816,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5OC)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.94', 'le': '0.23', 'lle': '2.78', 'sei': '5.89'}",CHEMBL3972861,,CHEMBL3972861,8.05,0,http://www.openphacts.org/units/Nanomolar,2885428,=,37,1,=,,IC50,nM,,8.996,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.996
,411001,17775817,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5F)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.76', 'le': '0.25', 'lle': '3.04', 'sei': '6.62'}",CHEMBL3946725,,CHEMBL3946725,8.44,0,http://www.openphacts.org/units/Nanomolar,2885429,=,37,1,=,,IC50,nM,,3.629,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.629
,411002,17775818,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@@H](COC)c5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.40', 'le': '0.24', 'lle': '3.08', 'sei': '6.24'}",CHEMBL3947778,,CHEMBL3947778,8.53,0,http://www.openphacts.org/units/Nanomolar,2885430,=,37,1,=,,IC50,nM,,2.947,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.947
,411003,17775819,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@H](CCO)c5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.20', 'le': '0.23', 'lle': '3.20', 'sei': '5.68'}",CHEMBL4109025,,CHEMBL4109025,8.39,0,http://www.openphacts.org/units/Nanomolar,2885431,=,37,1,=,,IC50,nM,,4.059,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.059
,411004,17775820,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n([C@H](COC)c5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.25', 'le': '0.23', 'lle': '2.97', 'sei': '6.17'}",CHEMBL4107186,,CHEMBL4107186,8.42,0,http://www.openphacts.org/units/Nanomolar,2885432,=,37,1,=,,IC50,nM,,3.768,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.768
,411005,17775821,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3ccc4nc(C)n(Cc5ccc(F)cc5)c(=O)c4n3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.44', 'le': '0.26', 'lle': '3.39', 'sei': '6.79'}",CHEMBL3925436,,CHEMBL3925436,8.65,0,http://www.openphacts.org/units/Nanomolar,2885433,=,37,1,=,,IC50,nM,,2.244,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.244
,411006,17775822,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc(OC)c4nc(C)n(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '11.89', 'le': '0.23', 'lle': '2.12', 'sei': '6.46'}",CHEMBL3983489,,CHEMBL3983489,8.00,0,http://www.openphacts.org/units/Nanomolar,2885434,=,37,1,=,,IC50,nM,,10.06,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.06
,411007,17775823,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(=O)n(Cc5ccc(F)cc5)nnc4cc3F)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.25', 'le': '0.25', 'lle': '3.49', 'sei': '6.74'}",CHEMBL3942127,,CHEMBL3942127,8.58,0,http://www.openphacts.org/units/Nanomolar,2885435,=,37,1,=,,IC50,nM,,2.609,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.609
,411008,17775824,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc(OC)c4nnn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '13.81', 'le': '0.26', 'lle': '4.15', 'sei': '6.67'}",CHEMBL3961240,,CHEMBL3961240,9.11,0,http://www.openphacts.org/units/Nanomolar,2885436,=,37,1,=,,IC50,nM,,0.7817,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.7817
,411009,17775825,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(=O)n(Cc5ccc(F)cc5)nnc4cc3C)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.72', 'le': '0.24', 'lle': '2.93', 'sei': '6.43'}",CHEMBL3986495,,CHEMBL3986495,8.19,0,http://www.openphacts.org/units/Nanomolar,2885437,=,37,1,=,,IC50,nM,,6.475,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.475
,411010,17775826,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc4c(=O)n(Cc5ccc(F)cc5)nnc4cc3Cl)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.22', 'le': '0.24', 'lle': '2.51', 'sei': '6.37'}",CHEMBL3949157,,CHEMBL3949157,8.12,0,http://www.openphacts.org/units/Nanomolar,2885438,=,37,1,=,,IC50,nM,,7.652,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.652
,411011,17775827,[],CHEMBL3888611,"ELISA-Based Assay: Stable neomycin phosphotransferase encoding replicons-harboring cell lines were used, so all cell lines were maintained under G418 selection prior to the assay. Potency was deteremined using a cell ELISA assay with an antibody to the replicons encoded NS3/4a protease. See Caterina Trozzi et al., In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor, 77(6) J. Virol. 3669 (2003). To initiate an assay, replicon cells were plated in the presence of a dilution series of test compound in the absence of G418. Typically, the assays were performed in a 96-well plate formate for manual operation, or a 384-well plate format for automated assay. Replicon cells and compound were incubated for 96 hours. At the end of the assay, cells were washed free of media and compound, and the cells were then lysed. RNA was quantified indirectly through detection of replicon-encoded NS3/4A protein levels, through an ELISA-based assay with an antibody specific for NS3/4A.",B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)c1c(-c2ccc(F)cc2)oc2cc(N(C)S(C)(=O)=O)c(-c3cc(C)c4nnn(Cc5ccc(F)cc5)c(=O)c4c3)cc12,,,CHEMBL3886778,,2016,"{'bei': '12.66', 'le': '0.24', 'lle': '2.89', 'sei': '6.40'}",CHEMBL3978278,,CHEMBL3978278,8.15,0,http://www.openphacts.org/units/Nanomolar,2885439,=,37,1,=,,IC50,nM,,7.079,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.079
,421974,17785033,[],CHEMBL3888899,"FRET Assay: The protocol is a modified FRET-based assay (v_02) from In Vitro Resistance Studies of HCV Serine Protease Inhibitors, 2004, JBC, vol. 279, No. 17, pp 17508-17514. Inherent potency of compounds was assessed against A156S, A156T, D168A, and D168V mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 L of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, N.Y.) for 30 min at 25 C. with a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were started with the addition of 45 L of the FRET substrate and monitored for 120 minutes at ex487/em514 through Quad monochromoters in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '11.90', 'le': '0.23', 'lle': '6.54', 'sei': '3.62'}",CHEMBL3921185,,CHEMBL3921185,6.51,0,http://www.openphacts.org/units/Nanomolar,2890979,=,37,1,=,,IC50,nM,,312.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,312.0
,421975,17785034,[],CHEMBL3888900,"FRET Assay: The protocol is a modified FRET-based assay (v_02) from In Vitro Resistance Studies of HCV Serine Protease Inhibitors, 2004, JBC, vol. 279, No. 17, pp 17508-17514. Inherent potency of compounds was assessed against A156S, A156T, D168A, and D168V mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 L of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, N.Y.) for 30 min at 25 C. with a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were started with the addition of 45 L of the FRET substrate and monitored for 120 minutes at ex487/em514 through Quad monochromoters in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '11.03', 'le': '0.21', 'lle': '6.06', 'sei': '3.36'}",CHEMBL3921185,,CHEMBL3921185,6.03,0,http://www.openphacts.org/units/Nanomolar,2890979,=,37,1,=,,IC50,nM,,928.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,928.0
,421976,17785035,[],CHEMBL3888901,"FRET Assay: The protocol is a modified FRET-based assay (v_02) from In Vitro Resistance Studies of HCV Serine Protease Inhibitors, 2004, JBC, vol. 279, No. 17, pp 17508-17514. Inherent potency of compounds was assessed against A156S, A156T, D168A, and D168V mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 L of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, N.Y.) for 30 min at 25 C. with a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were started with the addition of 45 L of the FRET substrate and monitored for 120 minutes at ex487/em514 through Quad monochromoters in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '10.91', 'le': '0.21', 'lle': '5.99', 'sei': '3.32'}",CHEMBL3921185,,CHEMBL3921185,5.96,0,http://www.openphacts.org/units/Nanomolar,2890979,=,37,1,=,,IC50,nM,,1090.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1090.0
,421978,17785037,[],CHEMBL3888899,"FRET Assay: The protocol is a modified FRET-based assay (v_02) from In Vitro Resistance Studies of HCV Serine Protease Inhibitors, 2004, JBC, vol. 279, No. 17, pp 17508-17514. Inherent potency of compounds was assessed against A156S, A156T, D168A, and D168V mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 L of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, N.Y.) for 30 min at 25 C. with a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were started with the addition of 45 L of the FRET substrate and monitored for 120 minutes at ex487/em514 through Quad monochromoters in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)=CC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '13.23', 'le': '0.25', 'lle': '5.19', 'sei': '4.61'}",CHEMBL3927196,,CHEMBL3927196,7.60,0,http://www.openphacts.org/units/Nanomolar,2890980,=,37,1,=,,IC50,nM,,25.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,25.0
,421980,17785039,[],CHEMBL3888899,"FRET Assay: The protocol is a modified FRET-based assay (v_02) from In Vitro Resistance Studies of HCV Serine Protease Inhibitors, 2004, JBC, vol. 279, No. 17, pp 17508-17514. Inherent potency of compounds was assessed against A156S, A156T, D168A, and D168V mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM HEPES, pH 7.8, 100 mM NaCl, 5 mM DTT and 20% glycerol. 5 L of each enzyme were pre-incubated in a Corning (#3573) 384-well, black, non-treated microtiter plate (Corning, N.Y.) for 30 min at 25 C. with a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were started with the addition of 45 L of the FRET substrate and monitored for 120 minutes at ex487/em514 through Quad monochromoters in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,,,CHEMBL3886880,,2016,"{'bei': '9.92', 'le': '0.19', 'lle': '6.31', 'sei': '3.36'}",CHEMBL3983582,,CHEMBL3983582,7.01,0,http://www.openphacts.org/units/Nanomolar,2890981,=,37,1,=,,IC50,nM,,98.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,98.0
,421982,17785041,[],CHEMBL3888903,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,Q0ZMF1,A156S,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,,CHEMBL3921185,,CHEMBL3921185,,0,http://www.openphacts.org/units/Nanomolar,2890979,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421983,17785042,[],CHEMBL3888904,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '10.23', 'le': '0.20', 'lle': '5.62', 'sei': '3.11'}",CHEMBL3921185,,CHEMBL3921185,5.59,0,http://www.openphacts.org/units/Nanomolar,2890979,=,37,1,=,,IC50,nM,,2550.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2550.0
,421984,17785043,[],CHEMBL3888905,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,,CHEMBL3921185,,CHEMBL3921185,,0,http://www.openphacts.org/units/Nanomolar,2890979,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421985,17785044,[],CHEMBL3888906,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)NC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,,CHEMBL3921185,,CHEMBL3921185,,0,http://www.openphacts.org/units/Nanomolar,2890979,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421987,17785046,[],CHEMBL3888903,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,Q0ZMF1,A156S,BAO_0000190,BAO_0000223,protein complex format,CC(C)=CC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,,CHEMBL3927196,,CHEMBL3927196,,0,http://www.openphacts.org/units/Nanomolar,2890980,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421988,17785047,[],CHEMBL3888904,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)=CC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '11.30', 'le': '0.22', 'lle': '4.08', 'sei': '3.94'}",CHEMBL3927196,,CHEMBL3927196,6.49,0,http://www.openphacts.org/units/Nanomolar,2890980,=,37,1,=,,IC50,nM,,321.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,321.0
,421989,17785048,[],CHEMBL3888905,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)=CC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '10.40', 'le': '0.20', 'lle': '3.57', 'sei': '3.62'}",CHEMBL3927196,,CHEMBL3927196,5.98,0,http://www.openphacts.org/units/Nanomolar,2890980,=,37,1,=,,IC50,nM,,1050.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1050.0
,421990,17785049,[],CHEMBL3888906,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)=CC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)N1CC2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C,,,CHEMBL3886880,,2016,"{'bei': '9.89', 'le': '0.19', 'lle': '3.27', 'sei': '3.45'}",CHEMBL3927196,,CHEMBL3927196,5.68,0,http://www.openphacts.org/units/Nanomolar,2890980,=,37,1,=,,IC50,nM,,2070.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2070.0
,421992,17785051,[],CHEMBL3888903,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,Q0ZMF1,A156S,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,,,CHEMBL3886880,,2016,,CHEMBL3983582,,CHEMBL3983582,,0,http://www.openphacts.org/units/Nanomolar,2890981,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421993,17785052,[],CHEMBL3888904,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,,,CHEMBL3886880,,2016,"{'bei': '8.40', 'le': '0.16', 'lle': '5.24', 'sei': '2.85'}",CHEMBL3983582,,CHEMBL3983582,5.94,0,http://www.openphacts.org/units/Nanomolar,2890981,=,37,1,=,,IC50,nM,,1150.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1150.0
,421994,17785053,[],CHEMBL3888905,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,,,CHEMBL3886880,,2016,,CHEMBL3983582,,CHEMBL3983582,,0,http://www.openphacts.org/units/Nanomolar,2890981,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421995,17785054,[],CHEMBL3888906,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1,,,CHEMBL3886880,,2016,,CHEMBL3983582,,CHEMBL3983582,,0,http://www.openphacts.org/units/Nanomolar,2890981,>,37,1,>,,IC50,nM,,3000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3000.0
,421997,17785056,[],CHEMBL3888903,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,Q0ZMF1,A156S,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(OC(=O)C(F)(F)F)C(=O)NC1CC1,,,CHEMBL3886880,,2016,"{'bei': '7.93', 'le': '0.15', 'lle': '4.78', 'sei': '2.93'}",CHEMBL3954962,,CHEMBL3954962,6.38,0,http://www.openphacts.org/units/Nanomolar,2890982,=,37,1,=,,IC50,nM,,412.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,412.0
,421998,17785057,[],CHEMBL3888907,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(OC(=O)C(F)(F)F)C(=O)NC1CC1,,,CHEMBL3886880,,2016,"{'bei': '7.46', 'le': '0.14', 'lle': '4.40', 'sei': '2.76'}",CHEMBL3954962,,CHEMBL3954962,6.01,0,http://www.openphacts.org/units/Nanomolar,2890982,=,37,1,=,,IC50,nM,,985.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,985.0
,421999,17785058,[],CHEMBL3888904,"FRET Assay: The protocol is a modified FRET-based assay (v_03) developed to evaluate compound potency, rank-order and resistance profiles against wild type and C159S, A156S, A156T, D168A, D168V, R155K mutants of the HCV NS3/4A 1b protease enzyme as follows: 10 stocks of NS3/4A protease enzyme from Bioenza (Mountain View, Calif.) and 1.13 5-FAM/QXL520 FRET peptide substrate from Anaspec (San Jose, Calif.) were prepared in 50 mM Tris-HCl, pH 7.5, 5 mM DTT, 2% CHAPS and 20% glycerol. 5 L of each enzyme were added to Corning (#3575) 384-well, black, microtiter plates (Corning, N.Y.) after spotting a 0.5 L volume of 50% DMSO and serially diluted compounds prepared in 50% DMSO. Protease reactions were immediately started after enzyme addition with the addition of 45 L of the FRET substrate and monitored for 60-90 minutes at ex485/em520 in a Synergy4 plate reader from BioTek (Winooski, Vt.).",B,,,BAO_0000190,BAO_0000223,protein complex format,C=CC(=O)NC[C@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(OC(=O)C(F)(F)F)C(=O)NC1CC1,,,CHEMBL3886880,,2016,"{'bei': '7.82', 'le': '0.15', 'lle': '4.68', 'sei': '2.89'}",CHEMBL3954962,,CHEMBL3954962,6.29,0,http://www.openphacts.org/units/Nanomolar,2890982,=,37,1,=,,IC50,nM,,508.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,508.0
,,18377664,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '11.06', 'le': '0.22', 'lle': '4.22', 'sei': '4.55'}",CHEMBL3921126,,CHEMBL3921126,8.30,0,http://www.openphacts.org/units/Nanomolar,3050389,=,1,1,=,,IC50,nM,,5.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,5.0
,,18377665,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3CC(F)F)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '9.99', 'le': '0.20', 'lle': '3.53', 'sei': '4.31'}",CHEMBL4177477,,CHEMBL4177477,7.85,0,http://www.openphacts.org/units/Nanomolar,3050388,=,1,1,=,,IC50,nM,,14.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,14.0
,,18377666,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C(F)(F)F)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '9.83', 'le': '0.20', 'lle': '3.54', 'sei': '4.26'}",CHEMBL4168149,,CHEMBL4168149,7.77,0,http://www.openphacts.org/units/Nanomolar,3050387,=,1,1,=,,IC50,nM,,17.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,17.0
,,18377667,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '10.71', 'le': '0.22', 'lle': '4.20', 'sei': '4.33'}",CHEMBL4176000,,CHEMBL4176000,7.89,0,http://www.openphacts.org/units/Nanomolar,3050386,=,1,1,=,,IC50,nM,,13.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,13.0
,,18377668,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@@]3(C(=O)NS(=O)(=O)C4CC4)C[C@@H]3C(F)F)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '10.26', 'le': '0.21', 'lle': '3.99', 'sei': '4.34'}",CHEMBL4171493,,CHEMBL4171493,7.92,0,http://www.openphacts.org/units/Nanomolar,3050385,=,1,1,=,,IC50,nM,,12.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,12.0
,,18377669,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C(F)F)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '11.65', 'le': '0.24', 'lle': '5.07', 'sei': '4.94'}",CHEMBL4160876,,CHEMBL4160876,9.00,0,http://www.openphacts.org/units/Nanomolar,3050384,=,1,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,,18377670,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)NC3(C(=O)NS(=O)(=O)C4CC4)CCC3)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '8.94', 'le': '0.18', 'lle': '2.75', 'sei': '3.61'}",CHEMBL4161286,,CHEMBL4161286,6.58,0,http://www.openphacts.org/units/Nanomolar,3050383,=,1,1,=,,IC50,nM,,261.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,261.0
,,18377671,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1ccc2c(O[C@@H]3C[C@@H](C(=O)NC(CC(F)F)C(=O)NS(=O)(=O)C4CC4)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C3)cc(-c3ccccc3)nc2c1,,,CHEMBL4138306,ACS Med Chem Lett,2018,,CHEMBL4169219,,CHEMBL4169219,,0,http://www.openphacts.org/units/Nanomolar,3050382,>,1,1,>,,IC50,nM,,1000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1000.0
,,18377672,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,CC[C@@H](NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '7.04', 'le': '0.14', 'lle': '1.41', 'sei': '2.80'}",CHEMBL4164707,,CHEMBL4164707,5.10,0,http://www.openphacts.org/units/Nanomolar,3050381,=,1,1,=,,IC50,nM,,7979.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7979.0
,,18377673,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,CC[C@H](NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '7.61', 'le': '0.15', 'lle': '1.82', 'sei': '3.02'}",CHEMBL4172603,,CHEMBL4172603,5.51,0,http://www.openphacts.org/units/Nanomolar,3050380,=,1,1,=,,IC50,nM,,3079.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3079.0
,,18377674,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@H](CC(F)F)C(=O)NS(=O)(=O)C3CC3)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '7.37', 'le': '0.15', 'lle': '1.68', 'sei': '3.07'}",CHEMBL4168077,,CHEMBL4168077,5.61,0,http://www.openphacts.org/units/Nanomolar,3050379,=,1,1,=,,IC50,nM,,2479.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2479.0
,,18377675,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@@H](CC(F)F)C(=O)NS(=O)(=O)C3CC3)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '7.91', 'le': '0.16', 'lle': '2.08', 'sei': '3.30'}",CHEMBL4160158,,CHEMBL4160158,6.01,0,http://www.openphacts.org/units/Nanomolar,3050378,=,1,1,=,,IC50,nM,,976.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,976.0
,,18377676,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)NC3(C(=O)NS(=O)(=O)C4CC4)CC3)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '10.24', 'le': '0.21', 'lle': '3.96', 'sei': '4.06'}",CHEMBL4159744,,CHEMBL4159744,7.40,0,http://www.openphacts.org/units/Nanomolar,3050377,=,1,1,=,,IC50,nM,,40.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,40.0
,,18377677,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)NC(C)(C)C(=O)NS(=O)(=O)C3CC3)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '7.81', 'le': '0.16', 'lle': '1.97', 'sei': '3.10'}",CHEMBL4170379,,CHEMBL4170379,5.66,0,http://www.openphacts.org/units/Nanomolar,3050376,=,1,1,=,,IC50,nM,,2194.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2194.0
,,18377678,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=CC[C@](C)(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '5.97', 'le': '0.12', 'lle': '0.24', 'sei': '2.46'}",CHEMBL4174861,,CHEMBL4174861,4.48,0,http://www.openphacts.org/units/Nanomolar,3050375,=,1,1,=,,IC50,nM,,33000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,33000.0
,,18377679,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cnc(O[C@@H]2C[C@@H](C(=O)N[C@]3(C(=O)NS(=O)(=O)C4CC4)C[C@H]3C3CC3)N(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C2)c2cc(Cl)ccc12,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '10.79', 'le': '0.22', 'lle': '4.14', 'sei': '4.51'}",CHEMBL3895075,,CHEMBL3895075,8.22,0,http://www.openphacts.org/units/Nanomolar,3050374,=,1,1,=,,IC50,nM,,6.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,6.0
,,18377680,[],CHEMBL4145025,Inhibition of recombinant full length HCV genotype 1a NS3/4A protease (1027 to 1711 residues) expressed in Escherichia coli strain BL21 (DE3) using RET S1 as substrate incubated for 1 min followed by substrate addition measured after 15 mins by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4138306,ACS Med Chem Lett,2018,"{'bei': '12.03', 'le': '0.24', 'lle': '5.15', 'sei': '4.94'}",CHEMBL2105735,ASUNAPREVIR,CHEMBL2105735,9.00,0,http://www.openphacts.org/units/Nanomolar,3050373,=,1,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,,18586571,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.19', 'le': '0.24', 'lle': '5.50', 'sei': '4.77'}",CHEMBL2403888,,CHEMBL2403888,8.70,0,http://www.openphacts.org/units/Nanomolar,3086604,=,1,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,2.1,2.0
,,18586572,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.03', 'le': '0.24', 'lle': '5.15', 'sei': '4.94'}",CHEMBL2105735,ASUNAPREVIR,CHEMBL2105735,9.00,1,http://www.openphacts.org/units/Nanomolar,3086605,=,1,1,=,,IC50,nM,,1.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.0
,,18586573,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.84', 'le': '0.25', 'lle': '6.38', 'sei': '4.95'}",CHEMBL4224705,,CHEMBL4224705,9.15,0,http://www.openphacts.org/units/Nanomolar,3086606,=,1,1,=,,IC50,nM,,0.7,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.7
,,18586574,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.97', 'le': '0.21', 'lle': '6.29', 'sei': '4.00'}",CHEMBL4225561,,CHEMBL4225561,8.46,0,http://www.openphacts.org/units/Nanomolar,3086607,=,1,1,=,,IC50,nM,,3.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.5
,,18586575,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.11', 'le': '0.24', 'lle': '7.17', 'sei': '4.42'}",CHEMBL4229052,,CHEMBL4229052,9.34,0,http://www.openphacts.org/units/Nanomolar,3086608,=,1,1,=,,IC50,nM,,0.46,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.46
,,18586576,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.26', 'le': '0.24', 'lle': '5.68', 'sei': '4.91'}",CHEMBL4225301,,CHEMBL4225301,9.09,0,http://www.openphacts.org/units/Nanomolar,3086609,=,1,1,=,,IC50,nM,,0.82,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.82
,,18586577,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '13.03', 'le': '0.25', 'lle': '6.25', 'sei': '5.22'}",CHEMBL4228791,,CHEMBL4228791,9.66,0,http://www.openphacts.org/units/Nanomolar,3086610,=,1,1,=,,IC50,nM,,0.22,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.22
,,18586578,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H]1C(=O)OCC1(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.93', 'le': '0.19', 'lle': '5.71', 'sei': '3.61'}",CHEMBL4225027,,CHEMBL4225027,7.64,0,http://www.openphacts.org/units/Nanomolar,3086611,=,1,1,=,,IC50,nM,,23.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,23.0
,,18586579,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H]1C(=O)OCC1(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.76', 'le': '0.23', 'lle': '7.12', 'sei': '4.28'}",CHEMBL4228533,,CHEMBL4228533,9.05,0,http://www.openphacts.org/units/Nanomolar,3086612,=,1,1,=,,IC50,nM,,0.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.9
,,18586580,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C)COC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.80', 'le': '0.23', 'lle': '6.59', 'sei': '4.43'}",CHEMBL4227401,,CHEMBL4227401,8.60,0,http://www.openphacts.org/units/Nanomolar,3086613,=,1,1,=,,IC50,nM,,2.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.5
,,18586581,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](CC)COC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.71', 'le': '0.23', 'lle': '6.30', 'sei': '4.48'}",CHEMBL4228282,,CHEMBL4228282,8.70,0,http://www.openphacts.org/units/Nanomolar,3086614,=,1,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,,18586582,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.36', 'le': '0.24', 'lle': '6.71', 'sei': '4.81'}",CHEMBL4229110,,CHEMBL4229110,9.36,0,http://www.openphacts.org/units/Nanomolar,3086615,=,1,1,=,,IC50,nM,,0.44,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.44
,,18586583,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)[C@@H](C)CC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.19', 'le': '0.24', 'lle': '6.36', 'sei': '4.84'}",CHEMBL4225514,,CHEMBL4225514,9.40,0,http://www.openphacts.org/units/Nanomolar,3086616,=,1,1,=,,IC50,nM,,0.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.4
,,18586584,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.35', 'le': '0.24', 'lle': '6.48', 'sei': '4.90'}",CHEMBL4225051,,CHEMBL4225051,9.52,0,http://www.openphacts.org/units/Nanomolar,3086617,=,1,1,=,,IC50,nM,,0.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.3
,,18586585,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)CC(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.57', 'le': '0.23', 'lle': '5.88', 'sei': '4.59'}",CHEMBL4227396,,CHEMBL4227396,8.92,0,http://www.openphacts.org/units/Nanomolar,3086618,=,1,1,=,,IC50,nM,,1.2,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.2
,,18586586,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)c1ccccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.85', 'le': '0.21', 'lle': '5.23', 'sei': '4.42'}",CHEMBL4226548,,CHEMBL4226548,8.59,0,http://www.openphacts.org/units/Nanomolar,3086619,=,1,1,=,,IC50,nM,,2.6,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.6
,,18586587,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)Cc1ccccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.35', 'le': '0.20', 'lle': '5.10', 'sei': '4.28'}",CHEMBL4226979,,CHEMBL4226979,8.33,0,http://www.openphacts.org/units/Nanomolar,3086620,=,1,1,=,,IC50,nM,,4.7,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.7
,,18586588,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.06', 'le': '0.24', 'lle': '6.91', 'sei': '4.48'}",CHEMBL4225768,,CHEMBL4225768,9.47,0,http://www.openphacts.org/units/Nanomolar,3086621,=,1,1,=,,IC50,nM,,0.34,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.34
,,18586589,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC(C)(C)C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.75', 'le': '0.23', 'lle': '5.99', 'sei': '4.60'}",CHEMBL4226876,,CHEMBL4226876,9.72,0,http://www.openphacts.org/units/Nanomolar,3086622,=,1,1,=,,IC50,nM,,0.19,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.19
,,18586590,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)O)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '13.36', 'le': '0.26', 'lle': '7.83', 'sei': '4.63'}",CHEMBL4226033,,CHEMBL4226033,10.30,0,http://www.openphacts.org/units/Nanomolar,3086623,=,1,1,=,,IC50,nM,,0.05,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.05
,,18586591,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(N)=O)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '12.49', 'le': '0.24', 'lle': '7.75', 'sei': '4.22'}",CHEMBL4228440,,CHEMBL4228440,9.62,0,http://www.openphacts.org/units/Nanomolar,3086624,=,1,1,=,,IC50,nM,,0.24,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.24
,,18586592,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)NCc1ccccc1)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.25', 'le': '0.22', 'lle': '5.97', 'sei': '4.52'}",CHEMBL4225009,,CHEMBL4225009,9.68,0,http://www.openphacts.org/units/Nanomolar,3086625,=,1,1,=,,IC50,nM,,0.21,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.21
,,18586593,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)N1CCN(c2ncccn2)CC1)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.43', 'le': '0.20', 'lle': '7.04', 'sei': '4.08'}",CHEMBL4225149,,CHEMBL4225149,9.57,0,http://www.openphacts.org/units/Nanomolar,3086626,=,1,1,=,,IC50,nM,,0.27,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,0.27
,,18586594,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.57', 'le': '0.20', 'lle': '3.48', 'sei': '4.58'}",CHEMBL414993,,CHEMBL414993,8.35,0,http://www.openphacts.org/units/Nanomolar,3086627,=,1,1,=,,IC50,nM,,4.5,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.5
,,18586595,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.57', 'le': '0.20', 'lle': '3.90', 'sei': '4.50'}",CHEMBL4224849,,CHEMBL4224849,8.34,0,http://www.openphacts.org/units/Nanomolar,3086628,=,1,1,=,,IC50,nM,,4.6,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.6
,,18586596,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.11', 'le': '0.19', 'lle': '3.52', 'sei': '4.37'}",CHEMBL4227183,,CHEMBL4227183,8.10,0,http://www.openphacts.org/units/Nanomolar,3086629,=,1,1,=,,IC50,nM,,8.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.0
,,18586597,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N(C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.76', 'le': '0.21', 'lle': '3.86', 'sei': '4.90'}",CHEMBL4229158,,CHEMBL4229158,8.64,0,http://www.openphacts.org/units/Nanomolar,3086630,=,1,1,=,,IC50,nM,,2.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.3
,,18586598,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](N(C)C(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '7.39', 'le': '0.14', 'lle': '1.09', 'sei': '3.42'}",CHEMBL4227273,,CHEMBL4227273,6.03,0,http://www.openphacts.org/units/Nanomolar,3086631,=,1,1,=,,IC50,nM,,945.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,945.0
,,18586599,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@H]([C@@H](C)CC)N(C)C(=O)NC1CCCC1)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.15', 'le': '0.18', 'lle': '2.53', 'sei': '4.23'}",CHEMBL4224783,,CHEMBL4224783,7.46,0,http://www.openphacts.org/units/Nanomolar,3086632,=,1,1,=,,IC50,nM,,35.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,35.0
,,18586600,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@H]([C@@H](C)CC)N(C)C(=O)NC(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.65', 'le': '0.20', 'lle': '3.77', 'sei': '4.85'}",CHEMBL4225716,,CHEMBL4225716,8.55,0,http://www.openphacts.org/units/Nanomolar,3086633,=,1,1,=,,IC50,nM,,2.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.8
,,18586601,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N(C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.01', 'le': '0.21', 'lle': '4.88', 'sei': '4.54'}",CHEMBL4228080,,CHEMBL4228080,8.00,0,http://www.openphacts.org/units/Nanomolar,3086634,=,1,1,=,,IC50,nM,,10.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,10.0
,,18586602,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N(C)[C@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '11.17', 'le': '0.22', 'lle': '6.26', 'sei': '4.33'}",CHEMBL4228402,,CHEMBL4228402,8.77,0,http://www.openphacts.org/units/Nanomolar,3086635,=,1,1,=,,IC50,nM,,1.7,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.7
,,18586603,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](OC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.98', 'le': '0.19', 'lle': '3.02', 'sei': '4.33'}",CHEMBL4228717,,CHEMBL4228717,7.89,0,http://www.openphacts.org/units/Nanomolar,3086636,=,1,1,=,,IC50,nM,,13.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,13.0
,,18586604,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](OC(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.92', 'le': '0.19', 'lle': '2.95', 'sei': '4.36'}",CHEMBL4225245,,CHEMBL4225245,7.96,0,http://www.openphacts.org/units/Nanomolar,3086637,=,1,1,=,,IC50,nM,,11.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.0
,,18586605,[],CHEMBL4223564,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 1a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](OC(=O)NC(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.21', 'le': '0.20', 'lle': '3.44', 'sei': '4.34'}",CHEMBL4228457,,CHEMBL4228457,7.92,0,http://www.openphacts.org/units/Nanomolar,3086638,=,1,1,=,,IC50,nM,,12.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,12.0
,,18586651,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.43', 'le': '0.18', 'lle': '3.53', 'sei': '3.69'}",CHEMBL2403888,,CHEMBL2403888,6.73,0,http://www.openphacts.org/units/Nanomolar,3086604,=,1,1,=,,IC50,nM,,187.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,187.0
,,18586652,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.14', 'le': '0.20', 'lle': '4.46', 'sei': '3.90'}",CHEMBL4224705,,CHEMBL4224705,7.23,0,http://www.openphacts.org/units/Nanomolar,3086606,=,1,1,=,,IC50,nM,,59.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,59.0
,,18586653,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.41', 'le': '0.16', 'lle': '4.32', 'sei': '3.07'}",CHEMBL4225561,,CHEMBL4225561,6.49,0,http://www.openphacts.org/units/Nanomolar,3086607,=,1,1,=,,IC50,nM,,327.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,327.0
,,18586654,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.70', 'le': '0.19', 'lle': '5.31', 'sei': '3.54'}",CHEMBL4229052,,CHEMBL4229052,7.48,0,http://www.openphacts.org/units/Nanomolar,3086608,=,1,1,=,,IC50,nM,,33.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,33.0
,,18586655,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.37', 'le': '0.18', 'lle': '3.53', 'sei': '3.75'}",CHEMBL4225301,,CHEMBL4225301,6.94,0,http://www.openphacts.org/units/Nanomolar,3086609,=,1,1,=,,IC50,nM,,114.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,114.0
,,18586656,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.96', 'le': '0.19', 'lle': '3.97', 'sei': '3.98'}",CHEMBL4228791,,CHEMBL4228791,7.38,0,http://www.openphacts.org/units/Nanomolar,3086610,=,1,1,=,,IC50,nM,,42.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,42.0
,,18586657,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C)COC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.28', 'le': '0.18', 'lle': '4.75', 'sei': '3.48'}",CHEMBL4227401,,CHEMBL4227401,6.76,0,http://www.openphacts.org/units/Nanomolar,3086613,=,1,1,=,,IC50,nM,,172.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,172.0
,,18586658,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](CC)COC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.31', 'le': '0.18', 'lle': '4.52', 'sei': '3.56'}",CHEMBL4228282,,CHEMBL4228282,6.92,0,http://www.openphacts.org/units/Nanomolar,3086614,=,1,1,=,,IC50,nM,,121.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,121.0
,,18586659,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.92', 'le': '0.19', 'lle': '4.86', 'sei': '3.86'}",CHEMBL4229110,,CHEMBL4229110,7.51,0,http://www.openphacts.org/units/Nanomolar,3086615,=,1,1,=,,IC50,nM,,31.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,31.0
,,18586660,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)[C@@H](C)CC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.08', 'le': '0.20', 'lle': '4.73', 'sei': '4.00'}",CHEMBL4225514,,CHEMBL4225514,7.77,0,http://www.openphacts.org/units/Nanomolar,3086616,=,1,1,=,,IC50,nM,,17.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,17.0
,,18586661,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.19', 'le': '0.20', 'lle': '4.81', 'sei': '4.04'}",CHEMBL4225051,,CHEMBL4225051,7.85,0,http://www.openphacts.org/units/Nanomolar,3086617,=,1,1,=,,IC50,nM,,14.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,14.0
,,18586662,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)CC(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.31', 'le': '0.18', 'lle': '4.14', 'sei': '3.69'}",CHEMBL4227396,,CHEMBL4227396,7.18,0,http://www.openphacts.org/units/Nanomolar,3086618,=,1,1,=,,IC50,nM,,66.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,66.0
,,18586663,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)c1ccccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.52', 'le': '0.16', 'lle': '3.38', 'sei': '3.47'}",CHEMBL4226548,,CHEMBL4226548,6.74,0,http://www.openphacts.org/units/Nanomolar,3086619,=,1,1,=,,IC50,nM,,184.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,184.0
,,18586664,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)Cc1ccccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.26', 'le': '0.16', 'lle': '3.42', 'sei': '3.42'}",CHEMBL4226979,,CHEMBL4226979,6.65,0,http://www.openphacts.org/units/Nanomolar,3086620,=,1,1,=,,IC50,nM,,226.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,226.0
,,18586665,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.84', 'le': '0.19', 'lle': '5.16', 'sei': '3.65'}",CHEMBL4225768,,CHEMBL4225768,7.72,0,http://www.openphacts.org/units/Nanomolar,3086621,=,1,1,=,,IC50,nM,,19.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,19.0
,,18586666,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC(C)(C)C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.74', 'le': '0.17', 'lle': '3.50', 'sei': '3.42'}",CHEMBL4226876,,CHEMBL4226876,7.23,0,http://www.openphacts.org/units/Nanomolar,3086622,=,1,1,=,,IC50,nM,,59.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,59.0
,,18586667,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)O)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.44', 'le': '0.20', 'lle': '5.58', 'sei': '3.62'}",CHEMBL4226033,,CHEMBL4226033,8.05,0,http://www.openphacts.org/units/Nanomolar,3086623,=,1,1,=,,IC50,nM,,9.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,9.0
,,18586668,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(N)=O)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.20', 'le': '0.20', 'lle': '5.98', 'sei': '3.44'}",CHEMBL4228440,,CHEMBL4228440,7.85,0,http://www.openphacts.org/units/Nanomolar,3086624,=,1,1,=,,IC50,nM,,14.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,14.0
,,18586669,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)NCc1ccccc1)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.88', 'le': '0.17', 'lle': '3.93', 'sei': '3.57'}",CHEMBL4225009,,CHEMBL4225009,7.64,0,http://www.openphacts.org/units/Nanomolar,3086625,=,1,1,=,,IC50,nM,,23.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,23.0
,,18586670,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)N1CCN(c2ncccn2)CC1)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.42', 'le': '0.16', 'lle': '5.19', 'sei': '3.29'}",CHEMBL4225149,,CHEMBL4225149,7.72,0,http://www.openphacts.org/units/Nanomolar,3086626,=,1,1,=,,IC50,nM,,19.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,19.0
,,18586671,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.80', 'le': '0.19', 'lle': '2.87', 'sei': '4.25'}",CHEMBL414993,,CHEMBL414993,7.75,0,http://www.openphacts.org/units/Nanomolar,3086627,=,1,1,=,,IC50,nM,,18.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,18.0
,,18586672,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.34', 'le': '0.20', 'lle': '3.71', 'sei': '4.40'}",CHEMBL4224849,,CHEMBL4224849,8.15,0,http://www.openphacts.org/units/Nanomolar,3086628,=,1,1,=,,IC50,nM,,7.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.0
,,18586673,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.61', 'le': '0.20', 'lle': '3.91', 'sei': '4.59'}",CHEMBL4227183,,CHEMBL4227183,8.49,0,http://www.openphacts.org/units/Nanomolar,3086629,=,1,1,=,,IC50,nM,,3.2,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.2
,,18586674,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N(C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.04', 'le': '0.19', 'lle': '3.28', 'sei': '4.57'}",CHEMBL4229158,,CHEMBL4229158,8.06,0,http://www.openphacts.org/units/Nanomolar,3086630,=,1,1,=,,IC50,nM,,8.7,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,8.7
,,18586675,[],CHEMBL4223567,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 2b NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](OC(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.18', 'le': '0.16', 'lle': '1.55', 'sei': '3.60'}",CHEMBL4225245,,CHEMBL4225245,6.56,0,http://www.openphacts.org/units/Nanomolar,3086637,=,1,1,=,,IC50,nM,,277.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,277.0
,,18586676,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.84', 'le': '0.19', 'lle': '3.82', 'sei': '3.85'}",CHEMBL2403888,,CHEMBL2403888,7.02,0,http://www.openphacts.org/units/Nanomolar,3086604,=,1,1,=,,IC50,nM,,95.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,95.0
,,18586677,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.48', 'le': '0.20', 'lle': '4.70', 'sei': '4.03'}",CHEMBL4224705,,CHEMBL4224705,7.47,0,http://www.openphacts.org/units/Nanomolar,3086606,=,1,1,=,,IC50,nM,,34.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,34.0
,,18586678,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.25', 'le': '0.16', 'lle': '4.19', 'sei': '3.01'}",CHEMBL4225561,,CHEMBL4225561,6.36,0,http://www.openphacts.org/units/Nanomolar,3086607,=,1,1,=,,IC50,nM,,433.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,433.0
,,18586679,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.27', 'le': '0.18', 'lle': '4.98', 'sei': '3.38'}",CHEMBL4229052,,CHEMBL4229052,7.15,0,http://www.openphacts.org/units/Nanomolar,3086608,=,1,1,=,,IC50,nM,,71.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,71.0
,,18586680,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.18', 'le': '0.18', 'lle': '3.39', 'sei': '3.67'}",CHEMBL4225301,,CHEMBL4225301,6.80,0,http://www.openphacts.org/units/Nanomolar,3086609,=,1,1,=,,IC50,nM,,158.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,158.0
,,18586681,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.57', 'le': '0.19', 'lle': '3.68', 'sei': '3.83'}",CHEMBL4228791,,CHEMBL4228791,7.09,0,http://www.openphacts.org/units/Nanomolar,3086610,=,1,1,=,,IC50,nM,,81.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,81.0
,,18586682,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](C)COC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.29', 'le': '0.18', 'lle': '4.76', 'sei': '3.48'}",CHEMBL4227401,,CHEMBL4227401,6.77,0,http://www.openphacts.org/units/Nanomolar,3086613,=,1,1,=,,IC50,nM,,170.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,170.0
,,18586683,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@@H](CC)COC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.11', 'le': '0.18', 'lle': '4.37', 'sei': '3.48'}",CHEMBL4228282,,CHEMBL4228282,6.77,0,http://www.openphacts.org/units/Nanomolar,3086614,=,1,1,=,,IC50,nM,,171.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,171.0
,,18586684,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)C(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.54', 'le': '0.19', 'lle': '4.57', 'sei': '3.72'}",CHEMBL4229110,,CHEMBL4229110,7.22,0,http://www.openphacts.org/units/Nanomolar,3086615,=,1,1,=,,IC50,nM,,60.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,60.0
,,18586685,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)[C@@H](C)CC)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.26', 'le': '0.18', 'lle': '4.10', 'sei': '3.67'}",CHEMBL4225514,,CHEMBL4225514,7.14,0,http://www.openphacts.org/units/Nanomolar,3086616,=,1,1,=,,IC50,nM,,72.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,72.0
,,18586686,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.84', 'le': '0.19', 'lle': '4.55', 'sei': '3.90'}",CHEMBL4225051,,CHEMBL4225051,7.58,0,http://www.openphacts.org/units/Nanomolar,3086617,=,1,1,=,,IC50,nM,,26.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,26.0
,,18586687,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)CC(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.69', 'le': '0.17', 'lle': '3.66', 'sei': '3.45'}",CHEMBL4227396,,CHEMBL4227396,6.70,0,http://www.openphacts.org/units/Nanomolar,3086618,=,1,1,=,,IC50,nM,,201.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,201.0
,,18586688,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)c1ccccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '7.94', 'le': '0.15', 'lle': '2.92', 'sei': '3.23'}",CHEMBL4226548,,CHEMBL4226548,6.28,0,http://www.openphacts.org/units/Nanomolar,3086619,=,1,1,=,,IC50,nM,,524.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,524.0
,,18586689,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](COC)Cc1ccccc1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.17', 'le': '0.16', 'lle': '3.35', 'sei': '3.38'}",CHEMBL4226979,,CHEMBL4226979,6.58,0,http://www.openphacts.org/units/Nanomolar,3086620,=,1,1,=,,IC50,nM,,265.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,265.0
,,18586690,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.41', 'le': '0.18', 'lle': '4.83', 'sei': '3.49'}",CHEMBL4225768,,CHEMBL4225768,7.39,0,http://www.openphacts.org/units/Nanomolar,3086621,=,1,1,=,,IC50,nM,,41.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,41.0
,,18586691,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)OC(C)(C)C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.50', 'le': '0.17', 'lle': '3.30', 'sei': '3.33'}",CHEMBL4226876,,CHEMBL4226876,7.03,0,http://www.openphacts.org/units/Nanomolar,3086622,=,1,1,=,,IC50,nM,,93.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,93.0
,,18586692,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)O)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.32', 'le': '0.20', 'lle': '5.49', 'sei': '3.58'}",CHEMBL4226033,,CHEMBL4226033,7.96,0,http://www.openphacts.org/units/Nanomolar,3086623,=,1,1,=,,IC50,nM,,11.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.0
,,18586693,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(N)=O)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.13', 'le': '0.20', 'lle': '5.93', 'sei': '3.42'}",CHEMBL4228440,,CHEMBL4228440,7.80,0,http://www.openphacts.org/units/Nanomolar,3086624,=,1,1,=,,IC50,nM,,16.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,16.0
,,18586694,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)NCc1ccccc1)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.10', 'le': '0.18', 'lle': '4.11', 'sei': '3.65'}",CHEMBL4225009,,CHEMBL4225009,7.82,0,http://www.openphacts.org/units/Nanomolar,3086625,=,1,1,=,,IC50,nM,,15.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,15.0
,,18586695,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2nccc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N[C@H](C(=O)N1CCN(c2ncccn2)CC1)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '8.44', 'le': '0.16', 'lle': '5.21', 'sei': '3.30'}",CHEMBL4225149,,CHEMBL4225149,7.75,0,http://www.openphacts.org/units/Nanomolar,3086626,=,1,1,=,,IC50,nM,,18.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,18.0
,,18586696,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.80', 'le': '0.19', 'lle': '2.87', 'sei': '4.25'}",CHEMBL414993,,CHEMBL414993,7.75,0,http://www.openphacts.org/units/Nanomolar,3086627,=,1,1,=,,IC50,nM,,18.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,18.0
,,18586697,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '10.31', 'le': '0.20', 'lle': '3.69', 'sei': '4.39'}",CHEMBL4224849,,CHEMBL4224849,8.13,0,http://www.openphacts.org/units/Nanomolar,3086628,=,1,1,=,,IC50,nM,,7.4,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,7.4
,,18586698,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.73', 'le': '0.19', 'lle': '3.22', 'sei': '4.21'}",CHEMBL4227183,,CHEMBL4227183,7.80,0,http://www.openphacts.org/units/Nanomolar,3086629,=,1,1,=,,IC50,nM,,16.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,16.0
,,18586699,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](NC(=O)N(C)C(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '9.68', 'le': '0.19', 'lle': '2.99', 'sei': '4.41'}",CHEMBL4229158,,CHEMBL4229158,7.77,0,http://www.openphacts.org/units/Nanomolar,3086630,=,1,1,=,,IC50,nM,,17.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,17.0
,,18586700,[],CHEMBL4223568,Inhibition of N-terminal poly-His tagged recombinant HCV genotype 3a NS3/4A protease expressed in Escherichia coli BL21(DE3) pLysS using HCV-FRET peptide substrate by FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](OC(=O)NC1CCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4219218,Bioorg Med Chem Lett,2018,"{'bei': '7.57', 'le': '0.15', 'lle': '1.06', 'sei': '3.33'}",CHEMBL4225245,,CHEMBL4225245,6.07,0,http://www.openphacts.org/units/Nanomolar,3086637,=,1,1,=,,IC50,nM,,843.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,843.0
,,20597894,[],CHEMBL4602773,Inhibition of HCV NS3/4a protease using Ac-DE-Dap(QXL520)-EE-Abu-shi-[COO]AS-C(5-FAMsp)-NH2 as substrate after 15 mins,B,,,BAO_0000190,BAO_0000223,protein complex format,C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '11.34', 'le': '0.22', 'lle': '5.40', 'sei': '4.46'}",CHEMBL2063090,GRAZOPREVIR ANHYDROUS,CHEMBL2063090,8.70,0,http://www.openphacts.org/units/Nanomolar,3464696,=,1,1,=,,IC50,nM,,2.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,2.0
,,20597914,[],CHEMBL4602780,Inhibition of HCV NS3/4a protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1C[C@H](OCc2ccccc2)C[C@H]1C(=O)NC1(C(=O)O)CC1)C(C)C)C1CCCCC1,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '8.95', 'le': '0.17', 'lle': '7.24', 'sei': '2.54'}",CHEMBL4649647,,CHEMBL4649647,7.29,0,http://www.openphacts.org/units/Nanomolar,3464716,=,1,1,=,,IC50,nM,,51.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.051
,,20597915,[],CHEMBL4602780,Inhibition of HCV NS3/4a protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@@H](C(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1C[C@H](OCc2ccccc2)C[C@H]1C(=O)NC(CS)C(=O)O)C(C)C)C1CCCCC1,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '8.96', 'le': '0.18', 'lle': '7.66', 'sei': '2.61'}",CHEMBL4640558,,CHEMBL4640558,7.48,0,http://www.openphacts.org/units/Nanomolar,3464717,=,1,1,=,,IC50,nM,,33.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.033
,,20597916,[],CHEMBL4602780,Inhibition of HCV NS3/4a protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2cc(O[C@@H]3C[C@@H](C(=O)NC4(C(=O)O)CC4)N(C(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C4CCCCC4)C(C)C)C3)cnc2c1,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '9.35', 'le': '0.18', 'lle': '3.55', 'sei': '3.46'}",CHEMBL4632418,,CHEMBL4632418,6.10,0,http://www.openphacts.org/units/Nanomolar,3464718,=,1,1,=,,IC50,nM,,800.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,0.8
,,20597917,[],CHEMBL4602780,Inhibition of HCV NS3/4a protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)C[C@H](NC[C@H](CC(=O)O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H]1CCCC[C@H]1C(=O)O)C(N)=O,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '8.95', 'le': '0.17', 'lle': '3.04', 'sei': '2.57'}",CHEMBL4641913,,CHEMBL4641913,4.82,0,http://www.openphacts.org/units/Nanomolar,3464719,=,1,1,=,,IC50,nM,,15000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,15.0
,,20597974,[],CHEMBL4602773,Inhibition of HCV NS3/4a protease using Ac-DE-Dap(QXL520)-EE-Abu-shi-[COO]AS-C(5-FAMsp)-NH2 as substrate after 15 mins,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)(C)OC(=O)N[C@H]1CCCCC/C=C\[C@@H]2C[C@@]2(C(=O)NS(=O)(=O)C2CC2)NC(=O)[C@@H]2C[C@@H](OC(=O)N3Cc4cccc(F)c4C3)CN2C1=O,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '13.25', 'le': '0.26', 'lle': '6.56', 'sei': '5.37'}",CHEMBL258734,DANOPREVIR,CHEMBL258734,9.70,0,http://www.openphacts.org/units/Nanomolar,3464690,=,1,1,=,,IC50,nM,,0.2,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,3.5,0.2
,,20597977,[],CHEMBL4602773,Inhibition of HCV NS3/4a protease using Ac-DE-Dap(QXL520)-EE-Abu-shi-[COO]AS-C(5-FAMsp)-NH2 as substrate after 15 mins,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C/CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C,,,CHEMBL4602603,Eur J Med Chem,2019,"{'bei': '11.36', 'le': '0.22', 'lle': '3.27', 'sei': '5.43'}",CHEMBL4287268,,CHEMBL4287268,8.52,0,http://www.openphacts.org/units/Nanomolar,3464694,=,1,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,28.2,3.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24815594,[],CHEMBL5138460,Inhibition of HCV GT-1b NS3/4A protease measured by fluorescence assay,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1cc(NC(=O)Cc2csc(NS(=O)(=O)c3ccccc3)n2)ccc1Br,,,CHEMBL5137003,Bioorg Med Chem,2022,"{'bei': '12.13', 'le': '0.29', 'lle': '1.46', 'sei': '6.42'}",CHEMBL4448001,,CHEMBL4448001,5.66,0,http://www.openphacts.org/units/Nanomolar,3875033,=,1,1,=,,IC50,nM,,2200.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,2.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24815595,[],CHEMBL5138461,Inhibition of HCV GT-3a NS3/4A protease measured by fluorescence assay,B,,,BAO_0000190,BAO_0000223,protein complex format,Cc1ccc(S(=O)(=O)Nc2ccccc2C(=O)Nc2nc3c(Cl)ccc(Cl)c3s2)cc1,,,CHEMBL5137003,Bioorg Med Chem,2022,"{'bei': '11.77', 'le': '0.26', 'lle': '-0.16', 'sei': '6.57'}",CHEMBL4517125,,CHEMBL4517125,5.80,0,http://www.openphacts.org/units/Nanomolar,3875034,=,1,1,=,,IC50,nM,,1600.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,1.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24815597,[],CHEMBL5138463,Inhibition of HCV GT1b recombinant NS3/4A protease using Ac-Glu-Glu-Val-Val-Ala-Cys-AMC as substrate and measured by fluorescence based assay,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(C)c1ccc(NC(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)NCCCN2CCCCC2)cc1,,,CHEMBL5137003,Bioorg Med Chem,2022,"{'bei': '10.90', 'le': '0.20', 'lle': '0.32', 'sei': '5.98'}",CHEMBL5192990,,CHEMBL5192990,5.34,0,http://www.openphacts.org/units/Nanomolar,3875036,=,1,1,=,,IC50,nM,,4600.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,4.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24815599,[],CHEMBL5138465,Inhibition of HCV GT-3a NS3/4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,[2H]C([2H])([2H])Oc1cc2ccnc(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6(C)CC6)C[C@H]5/C=C/CC[C@@H](C)C[C@@H](CC)[C@H](NC(=O)OC(C)(C)C(F)(F)F)C(=O)N4C3)c2cc1F,,,CHEMBL5137003,Bioorg Med Chem,2022,"{'bei': '9.74', 'le': '0.19', 'lle': '2.88', 'sei': '4.56'}",CHEMBL5172547,,CHEMBL5221296,8.32,0,http://www.openphacts.org/units/Nanomolar,3875037,=,1,1,=,,IC50,nM,,4.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24975079,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.25', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '75.0'}]",CHEMBL5224341,Inhibition of HCV NS3/4a protease in Huh7.5 SGR cells using [Ac-DE-D(Edans)-EE-Abu-[COO]AS-K(Dabcyl)-NH2] as substrate preincubated for 15 mins followed by substrate addition and incubated for 1 hr by FRET assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnc(C(=O)NCCOCCOCCOc2cc3c4c(cccc4c2)C(=O)N(C2CCC(=O)NC2=O)C3=O)cn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,,,CHEMBL5223100,J Med Chem,2022,"{'bei': '5.69', 'le': None, 'lle': None, 'sei': None}",CHEMBL5184599,,CHEMBL5184599,6.61,0,http://www.openphacts.org/units/Nanomolar,3902961,=,1,1,=,,IC50,nM,,247.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,247.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073206,[],CHEMBL5253533,Inhibition of Hepatitis C virus NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '12.85', 'le': '0.25', 'lle': '3.79', 'sei': '8.14'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,8.48,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,3.3,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073210,[],CHEMBL5253536,Inhibition of HCV NS4A-NS3 protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)N4C3)cc(-c3ccccc3)nc2c1,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '12.20', 'le': '0.23', 'lle': '2.89', 'sei': '5.45'}",CHEMBL295844,,CHEMBL295844,8.52,0,http://www.openphacts.org/units/Nanomolar,3930248,=,1,1,=,,IC50,nM,,3.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,3.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073211,[],CHEMBL5253536,Inhibition of HCV NS4A-NS3 protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)[C@@H](C)CC)C(C)C)C(=O)O,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL5252531,J Med Chem,2016,,CHEMBL72695,,CHEMBL72695,,1,http://www.openphacts.org/units/Nanomolar,3930236,=,1,1,=,,IC50,nM,,150000.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,150.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073212,[],CHEMBL5253536,Inhibition of HCV NS4A-NS3 protease,B,,,BAO_0000190,BAO_0000223,protein complex format,CC(=O)N[C@H](C(=O)N[C@H](C(=O)N1C[C@H](OCc2cccc3ccccc23)C[C@H]1C(=O)NC1(C(=O)O)CC1)C(C)C)C1CCCCC1,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '8.60', 'le': '0.16', 'lle': '2.17', 'sei': '3.54'}",CHEMBL75558,,CHEMBL75558,5.46,0,http://www.openphacts.org/units/Nanomolar,3930237,=,1,1,=,,IC50,nM,,3500.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,uM,UO_0000065,,3.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073213,[],CHEMBL5253537,Inhibition of C-terminal HCV NS4A-NS3 protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)C[C@H]5/C=C\CCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)N4C3)cc(-c3ccccc3)nc2c1,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '11.39', 'le': '0.21', 'lle': '2.33', 'sei': '5.09'}",CHEMBL295844,,CHEMBL295844,7.96,0,http://www.openphacts.org/units/Nanomolar,3930248,=,1,1,=,,IC50,nM,,11.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,11.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073349,[],CHEMBL5253619,Inhibition of Hepatitis C virus genotype 1b NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '12.69', 'le': '0.24', 'lle': '3.69', 'sei': '8.04'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,8.38,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,4.2,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073350,[],CHEMBL5253620,Inhibition of Hepatitis C virus genotype 2a NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '10.28', 'le': '0.20', 'lle': '2.09', 'sei': '6.51'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,6.78,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,165.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,165.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073351,[],CHEMBL5253621,Inhibition of Hepatitis C virus genotype 2b NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '10.28', 'le': '0.20', 'lle': '2.10', 'sei': '6.51'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,6.79,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,164.0,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,164.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073352,[],CHEMBL5253622,Inhibition of Hepatitis C virus genotype 3a NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '13.25', 'le': '0.25', 'lle': '4.05', 'sei': '8.39'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,8.74,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,1.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,1.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073353,[],CHEMBL5253623,Inhibition of Hepatitis C virus genotype 4a NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '11.67', 'le': '0.22', 'lle': '3.01', 'sei': '7.39'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,7.70,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,19.9,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,19.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073354,[],CHEMBL5253624,Inhibition of Hepatitis C virus genotype 5a NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '12.61', 'le': '0.24', 'lle': '3.63', 'sei': '7.98'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,8.32,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,4.8,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,4.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25073355,[],CHEMBL5253625,Inhibition of Hepatitis C virus genotype 6a NS3/NS4A protease,B,,,BAO_0000190,BAO_0000223,protein complex format,COc1ccc2c(c1)[C@@H]1C[C@]1(C(=O)N1C3CCC1CN(C)C3)Cn1c-2c(C2CCCCC2)c2ccc(C(=O)NS(=O)(=O)N(C)C)cc21,,,CHEMBL5252531,J Med Chem,2016,"{'bei': '10.93', 'le': '0.21', 'lle': '2.52', 'sei': '6.92'}",CHEMBL3126842,BECLABUVIR,CHEMBL3126842,7.21,0,http://www.openphacts.org/units/Nanomolar,3930239,=,1,1,=,,IC50,nM,,61.6,CHEMBL2095231,Hepatitis C virus,"Hepatitis C virus serine protease, NS3/NS4A",3052230,,,IC50,nM,UO_0000065,,61.6
